JAK inhibitor compounds and their uses

Novel JAK inhibitor compounds, characterized by specific structural features, address the limitations of current JAK inhibitors by enhancing efficacy and safety for treating JAK-related diseases.

JP7580136B2Active Publication Date: 2024-11-11路良
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2022564690
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-30
Filing Date
2020-12-30
Publication Date
2024-11-11
Estimated Expiration
2040-12-30

AI Technical Summary

Technical Problem

Current JAK inhibitors for treating JAK-related diseases have limitations in efficacy and safety, necessitating the development of novel compounds with improved performance.

Method used

The development of novel JAK inhibitor compounds represented by formula (I), which include various substituents and functional groups, offering potential enhancements in efficacy and safety profiles.

Benefits of technology

The novel JAK inhibitor compounds demonstrate improved efficacy and safety profiles, providing more effective treatment options for JAK-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580136000001
    Figure 0007580136000001
  • Figure 0007580136000002
    Figure 0007580136000002
  • Figure 0007580136000003
    Figure 0007580136000003
Patent Text Reader

Abstract

This application relates to a JAK inhibitor compound and its use. Specifically, this application discloses a compound represented by formula (I), or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer, or isomeric mixture thereof, or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof. This application further relates to the medical use of said compound. [Formula 1] TIFF2023508772000092.tif51152
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to Chinese patent application No. 201911394671.X, entitled "JAK inhibitor compounds and their uses", filed on December 30, 2019, the entire contents of which are incorporated herein by reference.

[0002] The present application provides a class of novel compounds having pharmacological activity that can be used to inhibit Janus kinase (JAK). The present application further relates to compositions comprising said compounds, and the use of said compounds and said compositions in the preparation of medicaments for treating and / or preventing JAK-associated diseases or conditions. [Background technology]

[0003] Protein kinases are a family of enzymes that catalyze the phosphorylation of specific residues in proteins and are broadly classified into tyrosine kinases and serine / threonine kinases. Inappropriate kinase activity caused by mutations, overexpression or improper regulation, dysregulation or disregulation, and excessive or insufficient production of growth factors or cytokines is involved in many diseases, including but not limited to cancer, cardiovascular disease, allergies, asthma and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, metabolic disorders, neurological disorders, and neurodegenerative disorders (e.g., Alzheimer's disease). Inappropriate kinase activity leads to various biological cellular responses that are related to cell proliferation, cell differentiation, cell function, survival, apoptosis, and cell motility for the aforementioned and related diseases. Thus, protein kinases have become a type of important target kinase for therapeutic intervention. In particular, the JAK family of cellular protein tyrosine kinases plays an important role in cytokine signaling (Kisseleva et al., Gene, 2002, 285, 1; Yamaoka et al., Genome Biology, 2004, 5, 253).

[0004] Since the first JAK was discovered in the early 1990s, the development of JAK inhibitors has been around for nearly 30 years. JAKs are a family of intracellular non-receptor tyrosine kinases that play a role in cytokine receptor signaling pathways by interacting with signal transducers and activators of transcription (STATs). The JAK / STAT signaling pathway is involved in many important biological processes, such as cell proliferation, differentiation, apoptosis, and immune regulation. Compared with other signaling pathways, the transduction process of this signaling pathway is relatively simple and mainly consists of three components: tyrosine kinase associated receptors, tyrosine kinase JAKs, and signal transducers and activators of transcription STATs.

[0005] Many cytokines and growth factors, including interleukins (IL-2-7, IL-9, IL-10, IL-15, IL-21, etc.), GM-CSF (granulocyte / macrophage colony-stimulating factor, etc.), GH (growth hormone), EGF (epidermal growth factor), PRL (prolactin), EPO (erythropoietin), TPO (thrombopoietin), PDGF (platelet-derived factor), and interferons (including IFN-α, IFN-β, IFN-γ, etc.), transmit signals through the JAK-STAT signaling pathway. These cytokines and growth factors have corresponding receptors on the cell membrane. A common feature of these receptors is that the receptors themselves do not have kinase activity, but the intracellular segment has a binding site for the tyrosine kinase JAK. After the receptor binds to the ligand, the activation of the JAK bound to it phosphorylates the tyrosine residues of various target proteins, thereby realizing signal transmission from outside the cell to inside the cell.

[0006] JAK is a cytoplasmic tyrosine kinase that transmits cytokine signals from membrane receptors to STAT transcription factors. As mentioned above, JAK is an abbreviation of Janus kinase, and Janus is the two-faced god who governs beginnings and endings in Roman mythology. The reason it is called the two-faced god kinase is because it can phosphorylate cytokine receptors that are bound to JAK and phosphorylate multiple signal molecules that contain specific SH2 domains. The JAK protein family includes four members, JAK1, JAK2, JAK3, and TYK2, and these structures have seven JAK homology domains (JH), where the JH1 domain is a kinase domain whose function is to code for kinase proteins. The JH2 domain is a "pseudo" kinase domain that regulates the activity of JH1. JH3-JH7 form a four-in-one (4 in 1) domain that regulates the binding of JAK to the receptor.

[0007] STAT is a kind of cytoplasmic protein that can bind to DNA in the regulatory region of target genes and is a downstream substrate of JAK. Currently, seven members of the STAT family have been discovered, namely STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. The structure of STAT protein is divided into functional segments of N-terminal conserved sequence, DNA binding region, SH3 domain, SH2 domain and C-terminal transcription activation region. Among them, the most highly conserved and functionally important segment of the sequence is the SH2 domain, which has the core sequence "GTFLLRFSS" that is completely the same as the SH2 domain of tyrosine kinase Src.

[0008] The JAK-STAT signaling pathway has a wide range of functions and is involved in many important biological processes such as cell proliferation, differentiation, apoptosis, and immune regulation, and currently, most of the research related to disease and pharmaceutical innovation focuses on inflammatory diseases. Here, inflammatory diseases mainly include rheumatoid arthritis, canine dermatitis, psoriasis, ulcerative colitis, and Crohn's disease, and tumor diseases mainly include myelofibrosis, polycythemia vera, and primary platelet hyperplasia. In addition, mutations in the JAK molecule itself can cause acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), ductal carcinoma and non-small cell lung cancer (NSCLC), polycythemia vera (PV), idiopathic thrombocythemia (ET), idiopathic myelofibrosis (IMF), chronic myeloid leukemia (CML), etc.

[0009] JAK is a very important drug discovery target, and JAK inhibitors developed for this target are mainly used to select therapeutic drugs for blood diseases, tumors, rheumatoid arthritis, psoriasis, etc. JAK-1, JAK-2 and TYK-2 are expressed in all tissues and cells of the human body, and JAK-3 is mainly expressed in each hematopoietic tissue cell, and is mainly present in bone marrow cells, thymocytes, NK cells, activated B lymphocytes and T lymphocytes. Studies have shown that JAK2 inhibitors are suitable for myeloproliferative disorders (Santos et al., Blood, 2010, 115:1131; Barosi G. and Rosti V., Curr. Opin. Hematol., 2009, 16:129; Atallah E. and Versotvsek S., 2009 Exp. Rev. Anticancer Ther. 9:663), and JAK3 inhibitors are useful as immune inhibitors (e.g., U.S. Patent No. 6,313,129; Borie et al., Curr. Opin. Investigational Drugs, 2003, 4:1297).

[0010] Currently, JAK inhibitors approved by the FDA and EMA include Tofacitinib, Ruxolitinib, Oclacitinib, etc. JAK inhibitors in mid- to late-stage clinical trials include Filgotinib, Peficitinib, etc.

[0011] Tofacitinib is a JAK3 inhibitor developed by Pfizer and approved for sale by the FDA in November 2012 for the treatment of adult patients with moderate to severe rheumatoid arthritis who have an inadequate response or intolerance to methotrexate. It is the first oral JAK inhibitor approved for the treatment of RA. Later, in March 2013, a version under the trade name Xeljanz was approved for sale by the Japanese PMDA. On March 16, 2017, Pfizer China announced that its application for the market of an oral JAK inhibitor had been formally approved by the CFDA. The drug has been reported to be approved for the treatment of adult patients with moderate to severe rheumatoid arthritis who have an inadequate response or intolerance to methotrexate. Currently, tofacitinib is approaching approval for indications such as psoriasis, ulcerative colitis, and juvenile idiopathic arthritis. Clinical trials for the treatment of indications such as Crohn's disease and alopecia areata have already entered the mid-to-late stages of clinical trials. The main side effects of tofacitinib are serious infection rates and elevated low-density lipoprotein levels, with the most common side effects being upper respiratory tract infections, headache, diarrhea, stuffy nose, sore throat, and nasopharyngitis. In addition, clinical studies have reported that tofacitinib may cause side effects such as anemia and neutropenia.

[0012] [ka]

[0013] Ruxolitinib is a JAK1 and JAK2 inhibitor co-developed by Incyte and Novartis and approved for sale by the US FDA in November 2011, and is also the first approved drug specifically for the treatment of myelofibrosis. It was approved by the EMA in August 2012 and by the Japan PMDA in July 2014. The drug is marketed in the US by Incyte under the trade name Jakafi, and in Europe and Japan by Novartis under the trade name Jakavi. Ruxolitinib is currently undergoing multiple mid- to late-stage clinical trials, and indications include various cancers, GVHD (graft-versus-host disease), alopecia areata, allergic dermatitis, rheumatoid arthritis, vitiligo, and psoriasis. The most common hematological side effects of ruxolitinib (incidence >20%) are decreased platelet count and anemia. The most common non-hematologic side effects (incidence >10%) were ecchymosis, dizziness, and headache.

[0014] [ka]

[0015] Oclacitinib was approved by the US FDA in 2013 for the control of itch and atopic dermatitis in canines due to allergic dermatitis. Oclacitinib is a novel JAK and JAK1-dependent cytokine inhibitor. Oclacitinib is not only a highly effective JAK1 inhibitor, but also inhibits the function of JAK1-dependent cytokines in several anti-allergic, inflammatory, and pruritic responses. It has little effect on cytokines that are not involved in JAK1 activation. For the treatment of itch due to allergic dermatitis, oral administration of 0.4-0.6 mg / kg oclacitinib twice daily is safe and effective. During the treatment period, administration of oclacitinib can relieve itch within 24 hours. In experiments, more than 70% of experimental animals (dogs) had a reduction in itch response of more than 50% on the 7th day. However, oclacitinib cannot yet be used to treat human diseases.

[0016] [ka]

[0017] Filgotinib is a JAK1 inhibitor that completed Phase III clinical trials for the treatment of rheumatoid arthritis in September 2018. At the same time, studies of filgotinib for the treatment of ulcerative colitis and Crohn's disease are currently in Phase 2 / 3 clinical trials. Filgotinib is a selective JAK1 inhibitor with IC50 of 10nM, 28nM, 810nM, and 116nM for JAK1, JAK2, JAK3, and TYK2, respectively.

[0018] [ka]

[0019] Peficitinib is a JAK1 and JAK3 inhibitor developed by Astellas Pharma and is currently in Phase III clinical trials for the treatment of rheumatoid arthritis. Phase II clinical trials for the treatment of psoriasis have already been completed. Peficitinib is a novel oral JAK inhibitor. Peficitinib inhibits the enzyme activity of JAK1, JAK2, JAK3 and TYK2 with IC50 of 3.9nM, 5.0nM, 0.71nM and 4.8nM, respectively.

[0020] [ka]

[0021] Although some JAK inhibitors have been approved for sale and many are still in clinical research, these JAK inhibitors are not satisfactory in terms of efficacy and safety. Therefore, there is a constant need for JAK inhibitors with better efficacy and / or fewer side effects. Summary of the Invention

[0022] The present application aims to provide a novel JAK inhibitor that can be an alternative to conventional JAK inhibitors, thereby providing more options for the treatment of JAK-related diseases.

[0023] A further object of the present application is to provide a novel JAK inhibitor having superior efficacy and / or superior safety compared to conventional JAK inhibitors.

[0024] In a first aspect, the present application provides a compound of formula (I): [ka] or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomers thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, wherein L is C=O, O=S=O, CH2 or a connecting bond; X1 is N or CR 14 and X2 is N or CR 15 and X3 is N or CR 16 and R 13 is H, -C(=O)-R 20 , C 1-6 Alkyl or C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, 11-15 membered tricyclo, C 5-11 bicycloalkyl, 5-11 membered bicycloheteroalkyl, and R 13 is substituted with 0, 1, 2, 3 or 4 R1; and R 17 are H, -OH, -SH, -CN, halogens, -NO2, -SF5, -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10Aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl-, (5-10 membered heteroaryl)-C 1-4 Alkyl-, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each option within the group is selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 13 and R 17together with the L and N atoms to which they are attached form a 4-10 membered heterocycloalkyl, said 4-10 membered heterocycloalkyl being selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 18 and R 19 are H, -OH, -SH, -CN, halogens, -NO2, -SF5, -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl-, (5-10 membered heteroaryl)-C 1-4 Alkyl-, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each option within the group is selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 18 and R 19 are, together with the carbon atoms to which they are attached, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 3-10 Cycloalkyl and 4-10 membered heterocycloalkyl are halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; The number of R2 is 0, 1, 2, 3 or 4, and each R2 is H, halogen, -OH, -NO2, -CN, -SF5, -SH, -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 4-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each of the -SC 1-4 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl and 7-11 membered bicycloheteroaryl are substituted with halogen, -CN, -OH, C 1-4Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-OR 12 , -C(=O)H, -C(=O)R 12 , -C(=O)-N(R9)(R 10 ), -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 and optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of: Each R1 is H, halogen, -OH, -NO2, -CN, -SF5, -SH, -SC 1-4 Alkyl, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-8 Alkoxy, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, 11-15 membered tricyclo, C 5-11 Bicycloalkyl, 5-11 membered bicycloheteroalkyl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each of the -SC 1-4 Alkyl, C1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-8 The alkoxy is optionally substituted with 1, 2, 3 or 4 R3 and 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 bicycloaryl, 7-11 membered bicycloheteroaryl is optionally substituted with 1, 2, 3 or 4 R4; R 14 , R 15 , R 16 are H, -OH, -SH, -CN, halogens, -NO2, -SF5, -SC 1-4 Alkyl, C 1-6 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each of the -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl and 3- to 7-membered heterocycloalkyl are halogen, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 substituted with 1, 2 or 3 substituents selected from haloalkoxy; R 20 are H, -OH, -SH, -CN, halogens, -NO2, -SF5, -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkekir, C. 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl-, (5-10 membered heteroaryl)-C 1-4 Alkyl-, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 where the options within the group are halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R3 and R4 are H, halogen, -OH, -NO2, -CN, -SF5, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, -N(R5)(R6), -N(R 11 )(C(=O)R 12 ), -CON(R7)(R8), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each C is independently selected from 1-6 Alkyl, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11Bicycloaryl and 7-11 membered bicycloheteroaryl are substituted with halogen, -CN, -OH, C 1-4 Alkyl, C 1-6 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-OR 12 , -C(=O)H, -C(=O)R 12 , -C(=O)-N(R9)(R 10 ), -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 and optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of: R5, R6, R7, R8, R9, R 10 , R 11 , R 12 are each independently H or C 1-6 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl- and (5-10 membered heteroaryl)-C 1-4 alkyl-, where each member within the group is selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 Alkyl)2, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 and optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of haloalkoxy.

[0025] Preferably, the present application relates to a compound of formula (I): [ka] or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomers thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, wherein L is C=O, O=S=O, CH2 or a connecting bond; X1 is N or CR 14 and X2 is N or CR 15 and X3 is N or CR 16 and R 13 , H, C 1-6 Alkyl or C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, 11-15 membered tricyclo, C 5-11 bicycloalkyl, 5-11 membered bicycloheteroalkyl, and R 13 is substituted with 0, 1, 2, 3 or 4 R1, and R 17 , H, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl-, (5-10 membered heteroaryl)-C 1-4 Alkyl-, -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -S(=O)2-N(R9)(R 10 ), where each option within the group is selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 13 and R 17 together with the L and N atoms to which they are attached form a 4-10 membered heterocycloalkyl, said 4-10 membered heterocycloalkyl being selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 18 and R 19 , H, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 Aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl-, (5-10 membered heteroaryl)-C 1-4 each independently selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 18 and R 19 are, together with the carbon atoms to which they are attached, C 3-10 cycloalkyl, 4-10 membered heterocycloalkyl, 3-10 Cycloalkyl and 4-10 membered heterocycloalkyl are halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; The number of R2 is 0, 1, 2, 3 or 4, and each R2 is H, halogen, -OH, -NO2, -CN, -SF5, -SH, -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 4-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each of the -SC 1-4 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl and 7-11 membered bicycloheteroaryl are substituted with halogen, -CN, -OH, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-OR 12 , -C(=O)H, -C(=O)R 12 , -C(=O)-N(R9)(R 10 ), -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 and optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of: Each R1 is H, halogen, -OH, -NO2, -CN, -SF5, -SH, -SC 1-4 Alkyl, C 1-8 Alkyl, C 2-8 Alkenyl, C2-8 Alkynyl, C 1-8 Alkoxy, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, 11-15 membered tricyclo, C 5-11 Bicycloalkyl, 5-11 membered bicycloheteroalkyl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each of the -SC 1-4 Alkyl, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-8 The alkoxy is optionally substituted with 1, 2, 3 or 4 R3 and 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 bicycloaryl, 7-11 membered bicycloheteroaryl is optionally substituted with 1, 2, 3 or 4 R4; R 14 , R 15 , R 16 are H, -OH, -SH, -CN, halogens, -NO2, -SF5, -SC 1-4 Alkyl, C 1-6 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7Aryl, 5-7 membered heteroaryl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-N(R9)(R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each of the -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl and 3- to 7-membered heterocycloalkyl are halogen, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 substituted with 1, 2 or 3 substituents selected from haloalkoxy; R3 and R4 are H, halogen, -OH, -NO2, -CN, -SF5, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11Bicycloaryl, 7-11 membered bicycloheteroaryl, -N(R5)(R6), -N(R 11 )(C(=O)R 12 ), -CON(R7)(R8), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 wherein each C is independently selected from 1-6 Alkyl, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl and 7-11 membered bicycloheteroaryl are substituted with halogen, -CN, -OH, C 1-4 Alkyl, C 1-6 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, -N(R9)(R 10 ), -N(R 11 )(C(=O)R 12 ), -C(=O)-OR 12 , -C(=O)H, -C(=O)R 12 , -C(=O)-N(R9)(R 10 ), -N(R 11 )(S(=O)2R 12 ), -S(=O)2-N(R9)(R 10 ), -SR 12 -OR 12 and optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of: R5, R6, R7, R8, R9, R 10 , R 11 , R 12 are each independently H or C 1-6 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C6-10 Aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4-10 membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl- and (5-10 membered heteroaryl)-C 1-4 alkyl-, where each member within the group is selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 Alkyl)2, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 and optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of haloalkoxy.

[0026] In some preferred embodiments of the present application, there is provided an isotopically labeled compound of the compound of formula (I) above. In some more preferred embodiments of the present application, there is provided an isotopically labeled compound of the compound of formula (I) above, wherein all H are each independently optionally replaced with D.

[0027] In some preferred embodiments of the present application, in formula (I), X1 is N. In some preferred embodiments of the present application, in formula (I), X2 is N. In some preferred embodiments of the present application, in formula (I), X3 is N. In some preferred embodiments of the present application, in formula (I), X1 is CR 14 and X2 is CR 15 And X3 is CR 16In some preferred embodiments of the present application, in formula (I), X1 is CR 14 and X2 is CR 15 And X3 is CR 16 and X1, X2, and X3 are H, -OH, -CN, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 cycloalkyl, and 3- to 7-membered heterocycloalkyl. In some preferred embodiments of the present application, in formula (I), X1, X2, and X3 are the same. In some preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all CH. In some preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all N.

[0028] In some more preferred embodiments of the present application, there is provided an isotopically labeled compound of the compound of formula (I), wherein all H are each separately optionally replaced with D, and X1, X2, and X3 are the same. In some more preferred embodiments of the present application, there is provided an isotopically labeled compound of the compound of formula (I), wherein all H are each separately optionally replaced with D, and X1, X2, and X3 are all CH.

[0029] In some preferred embodiments of the present application, in formula (I), L is C=O, O=S=O or CH2. In some particularly preferred embodiments of the present application, in formula (I), L is C=O. In some particularly preferred embodiments of the present application, in formula (I), L is O=S=O. In some particularly preferred embodiments of the present application, in formula (I), L is CH2. In other embodiments of the present application, in formula (I), L is a connecting bond.

[0030] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all CH, and L is C=O.

[0031] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all CH, and L is O=S=O.

[0032] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all CH, and L is CH2.

[0033] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all CH, and L is a connecting bond.

[0034] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all N, and L is C=O.

[0035] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all N, and L is O=S=O.

[0036] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all N, and L is CH2.

[0037] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are all N, and L is a connecting bond.

[0038] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are each CR 14 where R 14 -OH, -CN, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, and L is C=O.

[0039] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are each CR 14 where R 14-OH, -CN, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 cycloalkyl, 3-7 membered heterocycloalkyl, and L is O=S=O.

[0040] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are each CR 14 where R 14 -OH, -CN, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 cycloalkyl, 3- to 7-membered heterocycloalkyl, and L is CH2.

[0041] In some particularly preferred embodiments of the present application, in formula (I), X1, X2, and X3 are each CR 14 where R 14 -OH, -CN, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-7 cycloalkyl, 3- to 7-membered heterocycloalkyl, and L is a connecting bond.

[0042] In some preferred embodiments of the present application, in formula (I), R 13 , H, C 1-6 Alkyl or C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 bicycloaryl, 7-11 membered bicycloheteroaryl, 11-15 membered tricyclo (wherein R 13 is optionally substituted with 1, 2, 3 or 4 R. In some preferred embodiments of the present application, in formula (I), R 13 , H, C 1-6 Alkyl or C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 aryl, 5-7 membered heteroaryl (wherein R 13is optionally substituted with 1, 2, 3 or 4 R. In some preferred embodiments of the present application, in formula (I), R 13 is C 1-6 Alkyl or C 3-7 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, where R 13 is optionally substituted with 1, 2, 3 or 4 R. In some preferred embodiments of the present application, in formula (I), R 13 is C 1-4 Alkyl or C 3-7 cycloalkyl, 4-6 membered heterocycloalkyl, phenyl, 5-6 membered heteroaryl, where R 13 is optionally substituted with 1, 2, 3 or 4 R. In some preferred embodiments of the present application, in formula (I), R 13 is C 1-4 Alkyl or C 3-7 cycloalkyl, 4-6 membered heterocycloalkyl (wherein R 13 is optionally substituted with 1, 2, 3 or 4 R. In some preferred embodiments of the present application, in formula (I), R 13 is C 1-4 Alkyl or C 3-6 cycloalkyl, 5-6 membered heterocycloalkyl (wherein R 13 is optionally substituted with 1, 2, 3 or 4 R. In some preferred embodiments of the present application, in formula (I), R 13 is C 1-3 alkyl, cyclopropyl, or 6-membered heterocycloalkyl, 13 is optionally substituted with 1, 2, 3 or 4 R. In some preferred embodiments of the present application, in formula (I), R 13 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, or pyrazinyl, where R 13 is optionally substituted with 1, 2, 3 or 4 R. In some particularly preferred embodiments of the present application, in formula (I), R 13 In some particularly preferred embodiments of the present application, in formula (I), R 13In some particularly preferred embodiments of the present application, in formula (I), R 13 In some particularly preferred embodiments of the present application, in formula (I), R 13 In some particularly preferred embodiments of the present application, in formula (I), R 13 In some particularly preferred embodiments of the present application, in formula (I), R 13 In some particularly preferred embodiments of the present application, in formula (I), R 13 In some particularly preferred embodiments of the present application, in formula (I), R 13 is pyrazinyl and is substituted with morpholinyl.

[0043] In some preferred embodiments of the present application, in formula (I), R 17 are H, -OH, -SH, -CN, halogens, -NO2, -SF5, -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 Aryl or 5-10 membered heteroaryl, and halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 In some preferred embodiments of the present application, in formula (I), R 17 are H, -OH, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl, and also halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 In some preferred embodiments of the present application, in formula (I), R 17 is H, -OH or C 1-6 Alkyl and halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 In some particularly preferred embodiments of the present application, in formula (I), R 17 is H.

[0044] In some preferred embodiments of the present application, in formula (I), R 13 and R 17 together with the L and N atoms to which they are attached form a 4- to 6-membered heterocycloalkyl, said 4- to 6-membered heterocycloalkyl being selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-OC 1-4 Alkyl, -C(=O)-NH2, -C(=O)-N(C 1-4 alkyl)2, -N(C 1-4 Alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 In some preferred embodiments of the present application, in formula (I), R 13 and R 17 together with the L and N atoms to which they are attached form a 4- to 6-membered azacycloalkyl, said 4- to 6-membered azacycloalkyl being selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4In some preferred embodiments of the present application, in formula (I), R 13 and R 17 together with the L and N atoms to which they are attached form a 5-membered heterocycloalkyl, said 5-membered heterocycloalkyl being selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 In some particularly preferred embodiments of the present application, in formula (I), R 13 and R 17 together with the L and N atoms to which they are attached form pyrrolidinyl. In some particularly preferred embodiments of the present application, in formula (I), R 13 and R 17 together with the L and N atoms to which they are attached form a pyrrolidinyl, and the pyrrolidinyl is substituted with -OH.

[0045] In some preferred embodiments of the present application, in formula (I), R 18 and R 19 , H, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 each independently selected from the group consisting of halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -SC 1-4In some preferred embodiments of the present application, in formula (I), R 18 and R 19 , H, C 1-6 In some particularly preferred embodiments of the present application, in formula (I), R 18 is H. In some particularly preferred embodiments of the present application, in formula (I), R 19 is H. In some particularly preferred embodiments of the present application, in formula (I), R 18 , R 19 are both H.

[0046] In some preferred embodiments of the present application, in formula (I), R 18 and R 19 are, together with the carbon atoms to which they are attached, C 3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl, 3-6 Cycloalkyl and 4-6 membered heterocycloalkyl are halogen, -CF3, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, oxo, C 1-4 and optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of alkyl.

[0047] In some preferred embodiments of the present application, in formula (I), the number of R2 is 1, 2 or 3, and each R2 is H, halogen, -OH, -NO2, -CN, -SF5, -SH, -SC 1-4 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7cycloalkyl, and 4-10 membered heterocycloalkyl, wherein the -SC 1-4 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl and 4-10 membered heterocycloalkyl are halogen, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 In some preferred embodiments of the present application, the number of R2 in formula (I) is 1, 2 or 3, and each R2 is optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, C 1-6 Alkyl and C 3-6 cycloalkyl, wherein each of said C 1-6 Alkyl and C 3-6 Cycloalkyl is any of the following: halogen, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 In some preferred embodiments of the present application, the number of R2 in formula (I) is 1, 2 or 3, and each R2 is optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halogen, C 1-6 alkyl, wherein each of said C 1-6 Alkyl is a halogen, -OH, -NH2, -NH(CH3), -N(CH3)2, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 In some preferred embodiments of the present application, the number of R2 in formula (I) is 1 or 2, and each R2 is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, C 1-6In some preferred embodiments of the present application, in formula (I), the number of R2 is 1 or 2, and each R2 is independently selected from fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, and isobutyl. In some preferred embodiments of the present application, in formula (I), the number of R2 is 1 or 2, and each R2 is independently selected from fluorine, chlorine, methyl, ethyl, n-propyl, and isopropyl. In some preferred embodiments of the present application, in formula (I), the number of R2 is 1 or 2, and each R2 is independently selected from fluorine, methyl, and ethyl. In some preferred embodiments of the present application, in formula (I), the number of R2 is 1 or 2, and each R2 is independently selected from fluorine and ethyl. In some preferred embodiments of the present application, in formula (I), the number of R2 is 1 or 2, and each R2 is independently selected from fluorine and ethyl. In some preferred embodiments of the present application, in formula (I), the number of R2 is 1, and R2 is independently selected from fluorine and ethyl. In some preferred embodiments of the present application, in formula (I), the number of R2 is 2, and each R2 is selected from fluorine and ethyl. In some particularly preferred embodiments of the present application, in formula (I), there are two R2, which are fluorine and ethyl, respectively. In some particularly preferred embodiments of the present application, in formula (I), there is one R2, and R2 is ethyl. In some particularly preferred embodiments of the present application, in formula (I), there is one R2, and R2 is fluorine.

[0048] In some preferred embodiments of the present application, in formula (I), R 13 is substituted with 0, 1, 2, 3 or 4 R1, and each R1 is H, halogen, -OH, -NO2, -CN, -SF5, -SH, -SC 1-4 Alkyl, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-8 Alkoxy, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11bicycloaryl, 7- to 11-membered bicycloheteroaryl, 1-4 Alkyl, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-8 The alkoxy is optionally substituted with 1, 2, 3 or 4 R3 and 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl are optionally substituted with 1, 2, 3 or 4 R4. In some preferred embodiments of the present application, in formula (I), R 13 is substituted with 0, 1, 2, 3 or 4 R1, and each R1 is H, halogen, -OH, -NO2, -CN, -SF5, -SH, -SC 1-4 Alkyl, C 1-8 Alkyl, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 aryl, and 5- to 7-membered heteroaryl, 1-4 Alkyl, C 1-8 The alkyl is optionally substituted with 1, 2, 3 or 4 R3, and 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 The aryl, 5-7 membered heteroaryl are optionally substituted with 1, 2, 3 or 4 R4. In some preferred embodiments of the present application, in formula (I), R 13 is substituted with 0, 1, 2, 3 or 4 R1, and each R1 is a halogen, -OH, -CN, C 1-8 Alkyl, C 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7 aryl, 5- to 7-membered heteroaryl, 1-8 The alkyl is optionally substituted with 1, 2, 3 or 4 R3, and 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl, C 5-7The aryl, 5-7 membered heteroaryl are optionally substituted with 1, 2, 3 or 4 R4. In some preferred embodiments of the present application, in formula (I), R 13 is substituted with 0, 1, 2, 3 or 4 R1, and each R1 is a halogen, -OH, -CN, C 1-8 Alkyl, C 3-7 cycloalkyl, 3- to 7-membered heterocycloalkyl, 1-8 The alkyl is optionally substituted with 1, 2 or 3 R3, and 3-7 Cycloalkyl, 3-7 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R4. In some preferred embodiments of the present application, in formula (I), R 13 is substituted with 0, 1, 2, 3 or 4 R1, and each R1 is a halogen, -OH, C 1-6 Alkyl, C 3-7 cycloalkyl, 5- to 7-membered heterocycloalkyl, 1-6 The alkyl is optionally substituted with 1, 2 or 3 R3, and 3-7 Cycloalkyl, 5-7 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R4. In some preferred embodiments of the present application, in formula (I), R 13 is substituted with 0, 1, 2, 3 or 4 R1, and each R1 is a halogen, -OH, -CN, C 1-4 Alkyl, C 3-6 cycloalkyl, 5- to 7-membered heterocycloalkyl, 1-4 The alkyl is optionally selected from 1 or 2 R3 and 3-6 Cycloalkyl, 5-7 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R4. In some preferred embodiments of the present application, in formula (I), R 13 is substituted with 0, 1, 2, 3 or 4 R1, and each R1 is a 5- to 7-membered heterocycloalkyl, which is optionally substituted with 1, 2 or 3 R4. In some particularly preferred embodiments of the present application, in formula (I), R 13is substituted with 0 or 1 R1, and R1 is selected from piperidinyl or morpholinyl. In some particularly preferred embodiments of the present application, in formula (I), R1 is absent. In some particularly preferred embodiments of the present application, in formula (I), R 13 is substituted with one R. In some particularly preferred embodiments of the present application, in formula (I), R 13 is substituted with one R1, and R1 is piperidinyl. In some particularly preferred embodiments of the present application, in formula (I), R 13 is substituted with one R1, and R1 is morpholinyl.

[0049] The preferences for each substituent mentioned in the various preferred embodiments above can be combined with each other, and all of the various combinations are within the scope of the present application.

[0050] In the most preferred embodiments of the present application, the compound of formula (I) is each of the specific compounds set forth in each of the Examples herein, i.e., the compound of formula (I) is selected from: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-(piperidin-1-yl)pyrazine-2-carboxamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propionamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanecarboxamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)isobutyramide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methanesulfonamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-morpholinopyrazine-2-carboxamide, (S)-1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidin-3-ol, 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidin-4-ol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-N-methylcyclopropanecarboxamide, 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidine-4-nitrile, 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidine-3-carbonitrile, 5-ethyl-2-fluoro-4-(3-(4-(morpholinomethyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 5-ethyl-2-fluoro-4-(3-(4-((pyridin-3-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 5-ethyl-2-fluoro-4-(3-(4-(((1-methyl-1H-pyrazol-4-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 3-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-(2-hydroxyethyl)-1-methylurea, 4-(3-(4-(((cyclopropylmethyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanesulfonamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)ethanesulfonamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-hydroxypiperidine-1-carboxamide, (R)—N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxy-N-methylpyrrolidine-1-carboxamide, (R)—N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide, (S)—N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide, 5-ethyl-2-fluoro-4-(3-(4-(((2-hydroxyethyl)(methyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propane-2-sulfonamide, ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methyl carbamate, 2-cyanoethyl ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)carbamate, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclobutaneformamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methylpyrrolidine-3-carboxamide, 4-(3-(4-((2-azabicyclo[2.2.2]octan-2-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol, 4-(3-(4-((cyclobutylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol, 5-ethyl-2-fluoro-4-(3-(4-(((tetrahydrofuran-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 5-ethyl-2-fluoro-4-(3-(4-((pyridin-2-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methyl-1H-pyrazole-4-carboxamide, 5-ethyl-2-fluoro-4-(3-(4-(((1-methylpyrrolidin-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)morpholine-4-carboxamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-methylpiperazine-1-carboxamide, 5-Ethyl-4-(3-(4-((4-ethylpiperazin-1-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-2-fluorophenol. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0051] For brevity, any reference hereinafter to a "compound of formula (I)" or "a compound of formula (I)" or "a compound of the present application" also includes any optical isomer, geometric isomer, tautomer or mixture of isomers of a compound of formula (I).

[0052] The term "optical isomer" means that when a compound has one or more chiral centers, each chiral center can have an R or S configuration, whereby the various isomers formed are optically distinct. Optical isomers include all diastereomers, enantiomers, meso forms, racemates, or mixtures thereof. For example, optical isomers can be separated by chiral chromatographic columns or chiral synthesis.

[0053] The term "geometric isomer" refers to the presence of cis, trans, E and Z isomers in a compound when a double bond is present. Geometric isomers include cis, trans, E and Z isomers or mixtures thereof.

[0054] The term "tautomer" refers to an isomer produced by the rapid movement of an atom at two positions in a molecule. Those skilled in the art can understand that tautomers can be converted into each other and that under certain conditions, they can reach a state of equilibrium and coexist. The "compound represented by formula (I)" described herein also includes any tautomer of the compound represented by formula (I).

[0055] Unless otherwise specified, the term "compounds of formula (I)" or "compounds of formula (I)" or "compounds of the present application" referred to in this specification also includes isotopically labeled compounds obtained by replacing any atom of the compound with an isotope of the compound.

[0056] The present application includes all pharma- ceutically acceptable isotopically labeled compounds of formula (I) in which one or more atoms are replaced by an atom having the same atomic number as an atom commonly found in nature, but a different atomic mass or mass number.

[0057] As an example of application to isotopes contained in the compounds of the present application, 2 H(D) and 3 Hydrogen isotopes such as H(T), 11 C. 13 C and 14 Carbon isotopes such as C, 36 Isotopes of chlorine such as Cl, 18 Fluorine isotopes such as F, 123 I and 125 Iodine isotopes such as I 13 N and 15 Nitrogen isotopes such as N 15 O. 17 O and 18 Oxygen isotopes such as O, and 35 These include isotopes of sulfur such as S.

[0058] Certain isotopically labeled compounds of formula (I) (e.g., those containing a radioactive isotope) can be used in drug and / or substrate tissue distribution studies. For ease of incorporation and convenient detection methods, the deuterium (i.e. 2 H) and carbon-14 (i.e. 14C) is particularly useful for this purpose.

[0059] Deuterium (i.e. 2 Substitution with heavier isotopes, such as H), may offer certain therapeutic advantages and therefore may be preferred in certain circumstances, said therapeutic advantage being due to greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements).

[0060] Positron-emitting isotopes (e.g. 11 C. 18 F, 15 and 13 Substitution with N) can be used in Positron Emission Receptor Imaging (PET) studies to detect substrate receptor occupancy.

[0061] Isotopically labeled compounds of formula (I) are generally prepared by conventional techniques known to those skilled in the art, or by methods analogous to those described in the Examples and Preparations appended hereto, substituting an appropriate isotopically labeled reagent in place of a previously used non-labeled reagent.

[0062] The compounds of formula (I) may exist in the form of pharma- ceutically acceptable salts, for example, acid addition salts and / or base addition salts of the compounds of formula (I).Unless otherwise specified, "pharma-ceutically acceptable salts", as used herein, include acid addition salts or base addition salts that may appear in the compounds of formula (I).

[0063] Pharmaceutically acceptable salts of the compounds of formula (I) include their acid addition and base addition salts. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclohexaminesulfonate, ethanedisulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, 2-(4-hydroxybenzyl)benzoate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide. , 2-isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthalate, 2-hydroxyethanesulfonate, nicotinate, nitrate, orotate, oxalate, hexadecanoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, glucarate, stearate, salicylate, tannate, tartrate, tosylate and trifluoroacetate. Suitable base addition salts are formed from bases which form non-toxic salts. Examples include, but are not limited to, aluminum, arginine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, trometamol and zinc salts. In addition, it is also possible to form half salts of acids and bases, such as, for example, hemisulfate and hemicalcium salts. For a review of suitable salts, reference may be made to Handbook of Pharmaceutical Salts: Properties, Selection and Use by Stahl and Wermuth (Wiley-VCH, 2002). Methods for preparing pharma-ceutically acceptable salts of the compounds described herein are known to those skilled in the art.

[0064] Certain compounds of the present application can exist in unsolvated and solvated forms, including hydrated forms. In general, compounds of formula (I) can exist in solvated or unsolvated forms, both of which are within the scope of the present application.

[0065] Certain compounds of the present application may exist in different crystalline or amorphous forms, however, all compounds of formula (I) in whatever form they exist are included within the scope of the present application.

[0066] To avoid ambiguity, the following definitions are used herein. Unless otherwise specified, the terms used herein have the following meanings:

[0067] The term "pharmaceutical acceptable" means that the corresponding compound, carrier or molecule is suitable for administration to humans. Preferably, the term refers to those approved by regulatory agencies such as CFDA (China), EMEA (Europe), FDA (USA) for use in mammals, preferably humans.

[0068] "Prodrug" refers to a derivative that is converted to the compound of the present application under physiological conditions, for example, through oxidation, reduction, hydrolysis, etc. under enzyme catalysis, by reaction with enzymes, gastric acid, etc. in the body.

[0069] "Metabolite" refers to any molecule derived from any compound of the present application in a cell or organism, preferably a human.

[0070] The term "hydroxy" refers to --OH.

[0071] The term "halogen" or "halo" refers to -F, -Cl, -Br, or -I.

[0072] The term "cyano" refers to --CN.

[0073] In this application, when more than one substituent of a particular type is present, each substituent is selected independently, i.e., the substituents may be the same or different. For example, when there are 2, 3, or 4 R1, the R1 may be the same or different. For example, when there are 2, 3, or 4 R2, the R2 may be the same or different. For example, when R1 and R2 are both -N(R9)(R 10 ), then R9 and R 10 may be selected independently. That is, R in R and R in R may be the same or different. 10 and R at R2 10 may be the same or different. For example, when there are two R1 and both R1 are -N(R9)(R 10 ), then R9 and R 10 may be selected separately. That is, R9 in the first R1 and R9 in the second R1 may be the same or different, and R 10 and R in the second R1 10 may be the same or different. The above description applies to R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 applies to.

[0074] As used herein, the term "substituted" means that one or more (preferably 1 to 5, more preferably 1 to 3) hydrogen atoms in a substituent are separately replaced with the corresponding number of substituents.

[0075] As used herein, the term "separately" means that when the number of substituents exceeds one, these substituents may be the same or different.

[0076] As used herein, the terms "optionally" or "optionally" mean that a described event may or may not occur. For example, a group is "optionally substituted" means that the group may or may not be substituted.

[0077] As used herein, the term "heteroatom" refers to oxygen (O), nitrogen (N) or S (O). m where m can be 0, 1 or 2, i.e. represents a sulfur atom S, or a sulfoxide SO, or a sulfonyl S(O)2.

[0078] As used herein, the term "alkyl" refers to a saturated aliphatic hydrocarbon, including straight and branched chains. In some embodiments, an alkyl group has 1 to 8, or 1 to 6, or 1 to 3 carbon atoms. For example, "C 1-8 The term "alkyl" refers to a straight or branched chain group having 1 to 8 carbon atoms. 1-8 The term alkyl has the following definition: 1-6 The terms "alkyl", "C1-C3 alkyl" and "C1-C4 alkyl" include the terms. Examples of alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, isopentyl, neopentyl, (R)-2-methylbutyl, (S)-2-methylbutyl, 3-methylbutyl, 2,3-dimethylpropyl, 2,3-dimethylbutyl, hexyl, and the like. An alkyl group may be optionally substituted with one or more (e.g., 1 to 5) suitable substituents.

[0079] As used herein, the term "alkenyl" refers to an aliphatic hydrocarbon having at least one carbon-carbon double bond, including straight and branched chains having at least one carbon-carbon double bond. In some embodiments, an alkenyl group has 2-8 carbon atoms, 2-6 carbon atoms, 3-6 carbon atoms, or 2-4 carbon atoms. For example, "C 2-8 The term "alkenyl" refers to a straight or branched chain unsaturated group having 2 to 8 carbon atoms (having at least one carbon-carbon double bond). The double bond may or may not be the point of attachment of another group. Alkenyl includes, but is not limited to, vinyl, 1-propenyl, 2-propenyl, 2-methyl-2-propenyl, butenyl, pentenyl, 3-hexenyl, and the like. An alkenyl group may be optionally substituted with one or more (e.g., 1 to 5) suitable substituents. When a compound of formula (I) contains an alkenyl group, the alkenyl group may be present in a pure E form, a pure Z form, or any mixture thereof.

[0080] As used herein, the term "alkynyl" refers to an aliphatic hydrocarbon having at least one carbon-carbon triple bond, including straight and branched chains having at least one carbon-carbon triple bond. In some embodiments, alkynyl groups have 2-8 carbon atoms, 2-6 carbon atoms, 3-6 carbon atoms, or 2-4 carbon atoms. For example, "C 2-8 The term "alkynyl" refers to straight and branched chain unsaturated groups having 2 to 8 carbon atoms (having at least one carbon-carbon triple bond). The triple bond may or may not be the point of attachment of another group. Alkynyl includes, but is not limited to, ethynyl, 1-propynyl, 2-propynyl, 2-methyl-2-propynyl, butynyl, pentynyl, 3-hexynyl, and the like. Alkynyl groups may be optionally substituted with one or more (e.g., 1 to 5) suitable substituents.

[0081] As used herein, "C 3-7The term "cycloalkyl" refers to a cycloalkyl having 3 to 7 carbon atoms forming a ring, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl. Cycloalkyl may be optionally substituted with one or more suitable substituents.

[0082] As used herein, the term "n-membered heterocycloalkyl" refers to a cycloalkyl having m carbon atoms forming the ring and (n-m) heteroatoms forming the ring, the heteroatoms being selected from O, S and N. For example, 3-7 membered heterocycloalkyls include, but are not limited to, oxetane, thietane, azetidine, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, tetrahydropyran, tetrahydrothiopyran, piperidine, morpholine, piperazine, oxepane, thiepane, and azepane. Heterocycloalkyls may be optionally substituted with one or more suitable substituents.

[0083] As used herein, "C 5-7 The term "aryl" refers to an aryl having an aromatic ring containing from 5 to 7 carbon atoms, preferably phenyl.

[0084] As used herein, the term "n-membered heteroaryl" refers to a heteroaryl having m carbon atoms forming an aromatic ring and (n-m) heteroatoms forming an aromatic ring, said heteroatoms being selected from O, S and N. For example, 5-7 membered heteroaryls include, but are not limited to, pyrazine, pyrazole, pyrrole, furan, thiophene, thiazole and pyridine. Heteroaryls may be optionally substituted with one or more suitable substituents.

[0085] As used herein, "C 7-11 The term "bicycloaryl" refers to a bicycloaryl having 7 to 11 carbon atoms, such as naphthalene, indene, and the like, which may be optionally substituted with one or more suitable substituents.

[0086] As used herein, the term "n-membered bicycloheteroaryl group" refers to a bicycloheteroaryl having m carbon atoms forming an aromatic bicyclo and (n-m) heteroatoms forming an aromatic bicyclo, said heteroatoms being selected from O, S and N. For example, 7-11 membered bicycloheteroaryl include, but are not limited to, quinoline, isoquinoline, benzothiazole, and the like. Bicycloheteroaryl may be optionally substituted with one or more suitable substituents.

[0087] As used herein, the term "11-15 membered tricyclo" includes, but is not limited to, acridine and the like. The 11-15 membered tricyclo may be optionally substituted with one or more suitable substituents.

[0088] As used herein, the term "haloalkyl" refers to an alkyl group having one or more halogen substituents (up to the alkyl group being fully halogenated, i.e., every hydrogen atom of the alkyl group is replaced with a halogen atom). For example, "C 1-6 The term "haloalkyl" refers to a C alkyl group having one or more halogen substituents. 1-6 It refers to an alkyl group (wherein the alkyl group is fully halogenated, i.e., all hydrogen atoms in the alkyl group are replaced with halogen atoms). 1-4 The term "haloalkyl" refers to a C alkyl group having one or more halogen substituents. 1-4 Refers to an alkyl group (wherein the maximum alkyl group is fully halogenated, i.e., all hydrogen atoms of the alkyl group are replaced with halogen atoms). 1-3 The term "haloalkyl" refers to a C alkyl group having one or more halogen substituents. 1-3 Alkyl group (maximum alkyl group is fully halogenated, that is, each hydrogen atom of the alkyl group is replaced with a halogen atom). 1-2 The term "haloalkyl" refers to a C alkyl group having one or more halogen substituents. 1-2It refers to an alkyl group (i.e., methyl or ethyl) where the alkyl is fully halogenated, i.e., every hydrogen atom of the alkyl group is replaced with a halogen atom. As another example, the term "C1 haloalkyl" refers to a methyl group having one, two, or three halogen substituents. Examples of haloalkyl groups include CF3, C2F5, CHF2, CH2F, CH2CF3, CH2Cl, and the like.

[0089] As used herein, the term "alkoxy" refers to an alkyl that is singly bonded to an oxygen atom. The point of attachment of the alkoxy to the molecule is through the oxygen atom. An alkoxy is represented as alkyl-O-. 1―6 The term "alkoxy" refers to a straight or branched chain alkoxy having 1 to 6 carbon atoms. 1―6 The definition of the term alkoxy includes the term "C 1-3 The term "alkoxy" includes, but is not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, hexoxy, and the like. Alkoxy may be optionally substituted with one or more suitable substituents.

[0090] Numerical ranges relating to the number of substituents, carbon atoms, and ring atoms herein mean that every integer within the range is recited one by one, and ranges are used as shorthand notation only. For example, "1 to 4 substituents" means 1, 2, 3 or 4 substituents. "1 to 3 substituents" means 1, 2 or 3 substituents. The term "3- to 12-membered ring" means a 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, or 12-membered ring. The term "3- to 8-membered ring" means a 3-, 4-, 5-, 6-, 7-, or 8-membered ring. "1 to 12 carbon atoms" or "C 1-12" is a cyclic alkyl group consisting of one carbon atom (C1), two carbon atoms (C2), three carbon atoms (C3), four carbon atoms (C4), five carbon atoms (C5), six carbon atoms (C6), seven carbon atoms (C7), eight carbon atoms (C8), nine carbon atoms (C9), ten carbon atoms (C10), and seven carbon atoms (C11). 10 ), 11 carbon atoms (C 11 ) or 12 carbon atoms (C 12 ) "1 to 6 carbon atoms" or "C 1-6 " means one carbon atom (C1), two carbon atoms (C2), three carbon atoms (C3), four carbon atoms (C4), five carbon atoms (C5) or six carbon atoms (C6). "1 to 4 carbon atoms" or "C 1-4 " means one carbon atom (C1), two carbon atoms (C2), three carbon atoms (C3) or four carbon atoms (C4). "2 to 6 carbon atoms" or "C 2-6 " means 2 carbon atoms (C2), 3 carbon atoms (C3), 4 carbon atoms (C4), 5 carbon atoms (C5) or 6 carbon atoms (C6). "C 3-8 " means 3 carbon atoms (C3), 4 carbon atoms (C4), 5 carbon atoms (C5), 6 carbon atoms (C6), 7 carbon atoms (C7) or 8 carbon atoms (C8). "3 to 8 ring atoms" means 3, 4, 5, 6, 7 or 8 ring atoms.

[0091] Thus, the numerical ranges relating to the number of substituents, the number of carbon atoms, and the number of ring atoms also include any of the subranges, with each subrange also being considered to be disclosed herein.

[0092] In a second aspect, the present application provides a pharmaceutical composition comprising the compound described above, or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer, or mixture of isomers thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, and one or more pharma- ceutically acceptable carriers, adjuvants, or excipients.

[0093] The pharmaceutical composition of the present application may be prepared, as necessary, in a dosage form suitable for oral, topical (including, but not limited to, external application, spraying, etc.), parenteral (including subcutaneous, intramuscular, cortical and intravenous), bronchial or nasal administration. Preferably, the pharmaceutical composition of the present application is prepared in a dosage form (formulation) suitable for oral or topical administration. More preferably, the pharmaceutical composition of the present application is prepared in a dosage form (formulation) suitable for oral administration.

[0094] When a solid carrier is used, the preparation may be in the form of a tablet, placed in a hard capsule in powder or granule form, or in the form of a troche or lozenge. The solid carrier may contain conventional excipients, such as binders, fillers, tableting lubricants, disintegrants, wetting agents, and the like. If necessary, the tablets may be film-coated by conventional techniques. When a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, ointment, soft gel capsule, injectable sterile carrier, aqueous or non-aqueous liquid suspension, or may be a dry product that can be reconstituted with water or other suitable carrier before use. Liquid preparations may contain conventional additives, such as suspending agents, emulsifying agents, wetting agents, non-aqueous carriers (including edible oils), preservatives, and flavoring and / or coloring agents. For parenteral administration, the carrier will usually comprise at least mostly sterile water, although saline, glucose solutions, and the like may be used. Injectable suspensions may be used, in which case conventional suspending agents may be used. Conventional preservatives, buffers, and the like may be added to parenteral dosage forms. The pharmaceutical compositions are prepared by conventional techniques appropriate to the desired formulation containing appropriate amounts of the active ingredient (ie, a compound of formula (I) of the present application).

[0095] Compositions suitable for parenteral injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents and solvents include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc.), suitable mixtures thereof, vegetable oils (e.g., olive oil) and injectable organic esters (e.g., ethyl oleate).

[0096] These compositions may further contain various excipients, such as preservatives, wetting agents, emulsifying agents, and dispersing agents. To ensure inhibition of the action of microorganisms, various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, etc.) may be used. In addition, isotonic agents, such as sugars, sodium chloride, etc., may be included. Absorption of the injectable pharmaceutical form can be delayed by using agents that delay absorption (e.g., aluminum monostearate and gels).

[0097] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert diluent (or carrier) (e.g., sodium citrate or dicalcium phosphate), which may further include: (a) fillers or fillers (e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid), (b) binders (e.g., carboxymethylcellulose, alginic acid esters, gels, polyvinylpyrrolidone, sucrose, and gum arabic), (c) humectants (e.g., glycerol), (d) disintegrating agents (e.g., agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain synthetic silicic acid esters, sodium carbonate), (e) solution blocking agents (e.g., paraffin), (f) absorption promoters (e.g., quaternary ammonium compounds), (g) wetting agents (e.g., cetyl alcohol and glycerol monostearate), (h) adsorbents (e.g., kaolin and bentonite), and (i) lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate) or mixtures thereof.

[0098] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gel capsules using, for example, lactose as well as high molecular weight polyethylene glycols and other excipients.

[0099] Solid dosage forms (e.g., tablets, dragees, capsules, pills, and granules) can be prepared with coatings and shells (e.g., enteric coatings and others known in the art). They may contain light-blocking agents, and may further comprise an active compound or compositions of various active compounds that release the active compound or compounds in a delayed manner at a certain part of the intestinal tract. Examples of coating compositions that can be used are polymers and waxes. The active ingredient may also be in microencapsulated form, and may, if appropriate, contain one or more of the above-mentioned excipients.

[0100] Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, solutions, dispersions, syrups, and elixirs. In addition to the active compounds, liquid dosage forms may contain inert diluents (e.g., water or other solvents), solubilizers, and emulsifiers (e.g., ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butanediol, dimethylformamide), oils (e.g., cottonseed oil, peanut oil, corn oil, olive oil, castor oil, sesame oil), glycerin, tetrahydrofuranol, polyethylene glycol, and fatty acid esters of sorbitan, or mixtures of these substances, which are commonly used in the art.

[0101] Besides these inert diluents, the composition may also contain, for example, wetting agents, emulsifying and suspending agents, flavoring agents, seasonings, and aromatic agents.

[0102] Suspensions may contain, in addition to the active compound, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxylated ethylene sorbitol, sorbitan esters, microcrystalline fibers, metahydroxyaluminum, bentonite, agar-agar and Astragalus gel or mixtures of these substances.

[0103] Dosage forms for topical administration of the compounds of the present application include ointments, powders, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any necessary preservatives, buffers, or propellants. Ophthalmic formulations, eye ointments, powders and solutions are also included within the scope of the present application.

[0104] The topical dosage forms of the compounds of the present application are prepared in the form of water-in-oil (W / O) or oil-in-water (O / W) emulsions, for example in the form of water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O) emulsions, or in the form of aqueous or lipid dispersions, gels or aerosols.

[0105] The topical formulation of the compound of the present application may include additives and formulation aids such as emulsifiers, thickeners, gelling agents, water fixatives, diffusing agents, stabilizers, dyes, fragrances, and preservatives. Suitable emulsifiers include stearic acid, triethanolamine, and PEG-40-stearate. Suitable thickeners include glyceryl monostearate and PEG 600. Suitable preservatives include propylparaben and chlorocresol. Suitable diffusing agents include dimethylpolysiloxane and polydimethylcyclosiloxane. Suitable water fixatives include polyethylene glycol, preferably polyethylene glycol 600.

[0106] The topical dosage form of the compound of the present application may include ointments, lotions, gels, emulsions, microemulsions, sprays, skin patches, etc., which can be applied topically to treat skin diseases such as atopic dermatitis, eczema, psoriasis, scleroderma, pruritus, vitiligo, alopecia, etc. In particular, the topical dosage form of the compound of the present application is an ointment, which can be applied for topical external application to treat skin diseases such as atopic dermatitis, eczema, psoriasis, scleroderma, pruritus, vitiligo, alopecia, etc.

[0107] The amount of the compound of formula (I) in the pharmaceutical composition and dosage form can be appropriately determined by those skilled in the art according to the need. For example, the compound of formula (I) may be present in the pharmaceutical composition or dosage form in a therapeutically effective amount.

[0108] In a third aspect, the present application provides use of the above compound, or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of isomers thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or a composition as described above, in the preparation of a medicament for the treatment and / or prevention of a JAK-related disease or condition.

[0109] "JAK-associated diseases or conditions" include, but are not limited to, the following: Arthritis, including rheumatoid arthritis, juvenile arthritis, and psoriatic arthritis; The classification of autoimmune disorders includes single-organ or single-cell autoimmune disorders such as Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease, autoimmune thrombocytopenia, sympathetic ophthalmia, myasthenia gravis, Graves' disease, primary biliary cirrhosis, chronic aggressive hepatitis, ulcerative colitis and membranous glomerulopathy, as well as systemic autoimmune disorders (e.g. systemic lupus erythematosus, rheumatoid arthritis, Shogren's syndrome, Reiter's syndrome, polymyositis-dermatomyositis, systemic sclerosis, polyarteritis nodosa, multiple sclerosis, bullous pemphigoid), as well as other O-cell (humoral) or T-cell autoimmune disorders (including Cogan's syndrome), ankylosing spondylitis, Wegener's granulomatosis, autoimmune alopecia, type I or juvenile-onset diabetes mellitus or thyroiditis. and an autoimmune disease or condition, Cancers or tumors, including gastrointestinal / gastrointestinal cancer, colorectal cancer, liver cancer, skin cancer (including mast cell tumors and squamous cell carcinoma), breast and breast cancer, ovarian cancer, prostate cancer, lymphoma, leukemia (including acute myeloid leukemia and chronic myeloid leukemia), kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer, brain cancer, melanoma (including oral and metastatic melanoma), Kaposi's sarcoma, myeloma (including multiple myeloma), myeloproliferative disorders, proliferative diabetic retinopathy, or angiogenesis-related diseases (including solid tumors); Diabetes mellitus, including type 1 diabetes or diabetic complications; ocular diseases, conditions or conditions, including autoimmune diseases of the eye, keratoconjunctivitis, vernal conjunctivitis, uveitis (including Behcet's disease-related uveitis and phacouveitis), keratitis, herpetic keratitis, keratoconus, corneal epithelial dystrophia, corneal leukoplakia, ocular pemphigoid, Morin's ulcer, scleritis, Graves' ophthalmopathy, Vogt-Koyanagi-Harada syndrome, keratoconjunctivitis sicca (dry eye disease), bullae, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, sympathetic ophthalmia, allergic conjunctivitis, or ocular neovascularization; intestinal inflammation, allergy or condition, including Crohn's disease and / or ulcerative colitis, inflammatory bowel disease, celiac disease, proctitis, eosinophilic gastroenteritis or mastocytosis; Neurodegenerative diseases, including motor neuron disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, neurodegenerative diseases caused by cerebral ischemia or traumatic injury, glutamate neurotoxicity or hypoxia in stroke, ischemia / reperfusion injury in stroke, myocardial ischemia, renal ischemia, heart attack, cardiac hypertrophy, atherosclerosis and arteriosclerosis, organ hypoxia or platelet aggregation; skin diseases, conditions or illnesses, including atopic dermatitis, eczema, psoriasis, scleroderma, pruritus or other pruritic conditions, vitiligo, alopecia; allergies, including mammalian allergic dermatitis (including equine allergic diseases such as bite allergy), summer eczema, sweet itch, emphysema, inflammatory airway disease, recurrent airway obstruction, airway hyperresponsiveness, or chronic obstructive pulmonary disease; Asthma and other obstructive airways diseases, including chronic or refractory asthma, late stage asthma, bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma or dust induced asthma; Transplant rejection, including islet transplant rejection, bone marrow transplant rejection, graft versus host disease, organ and cell transplant rejection (e.g., bone marrow, cartilage, cornea, heart, intervertebral disc, pancreatic islet, kidney, limb, liver, lung, muscle, myoblast, nerve, pancreas, skin, small intestine or trachea) or xenografts.

[0110] In a fourth aspect, the present application provides a method for treating a JAK-related disease or condition, comprising administering a therapeutically effective amount of the above-mentioned compound, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of isomers thereof, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof, or a metabolite thereof, or the above-mentioned composition, to a patient in need thereof. Preferably, the patient is a mammal, more preferably a human patient. The route of administration can be oral, topical (including but not limited to external application, spray, etc.), parenteral (including subcutaneous, intramuscular, cortical, and intravenous), bronchial, or nasal. Preferably, the administration is oral or topical. More preferably, the administration is oral.

[0111] Surprisingly, the compounds of the present application have shown excellent efficacy as JAK kinase inhibitors in experiments (eg, superior to conventional JAK kinase inhibitors such as filgotinib) and have potentially good safety profiles.

[0112] The present application will be described in more detail below in combination with specific examples. EXAMPLES

[0113] The compound of formula (I) of the present application can be synthesized by various methods well known to those skilled in the art of organic synthesis. In the following specific examples, some exemplary synthetic methods of the compound of formula (I) are provided, and these methods are well known in the art of synthetic chemistry. Of course, referring to the exemplary solutions of the present invention, those skilled in the art can easily design the synthetic scheme of other compounds of formula (I) by appropriately adjusting reactants, reaction conditions and protective groups.

[0114] The present application will be further described below in conjunction with examples, but these examples are not intended to limit the scope of the present application.

[0115] Example 1: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-(piperidin-1-yl)pyrazine-2-carboxamide (MDI-3)

[0116] [ka]

[0117] Synthesis scheme of target compound 16 (i.e., MDI-3): [ka]

[0118] Synthesis scheme of intermediate 17 [ka]

[0119] Synthesis scheme of intermediate 19 [ka]

[0120] Synthesis scheme of intermediate 21 [ka]

[0121] Synthesis method: Intermediate 1: Synthesis of 5-ethyl-2-fluorophenol 5-Bromo-2-fluorophenol (200.0 mg, 1.05 mmol) and bis(tri-tert-butylphosphine)palladium (10.7 mg, 0.02 mmol) are dissolved in 10 ml of THF. The mixture is purged with nitrogen three times, cooled to 10-20°C, and 1 mol / L diethylzinc solution (2.3 ml, 2.30 mmol) is slowly dripped in. After dripping is completed, the mixture is heated to 50°C. The mixture is reacted overnight, cooled to 0°C, quenched by adding water, filtered through diatomaceous earth, the diatomaceous earth pad is washed with ethyl acetate, extracted with ethyl acetate, the organic phases are combined, washed with saturated sodium chloride solution, and dried over anhydrous sodium sulfate. After drying, the mixture is concentrated and separated by column chromatography to obtain an oily liquid, with a yield of 65.1%. 1 H NMR (400MHz, CDCl3) δ6.97(d,J=8.0Hz,1H),6.85(d,J=12.0Hz,1H),6.69-6.65(m,1H),2.61-2.55(m,2H),1.21(t,J=8.0Hz,3H).

[0122] Intermediate 2: Synthesis of 4-bromo-5-ethyl-2-fluorophenol Dissolve intermediate 1 (200.1 mg, 1.43 mmol) in 6 ml of acetonitrile, add CuBr2 (957.5 mg, 4.29 mmol), stir at room temperature for 3 hours, add water to quench, extract with ethyl acetate, wash the organic phase with saturated sodium chloride solution, dry with anhydrous sodium sulfate, concentrate and obtain a colorless oily product by column chromatography, the yield is 78.1%. 1 H NMR (400MHz, CDCl3) δ7.25(d,J=12.0Hz,1H),6.89(d,J=12.0Hz,1H),2.69-2.63(m,2H),1.19(t,J=12.0Hz,3H).

[0123] Intermediate 3: Synthesis of 2-((4-bromo-5-ethyl-2-fluorophenoxy)methoxy)ethyl)trimethylsilane Dissolve intermediate 2 (220.0 mg, 1.00 mmol) in 6 ml of DCM, add DIPEA (130.5 mg, 1.10 mmol) and cool to 0°C. Add SEMCl (168.2 mg, 1.10 mmol) dropwise at 0°C, and after the addition is complete, warm the reaction to room temperature and react for 8 hours, quench by adding water, extract with DCM, wash the organic phase with saturated sodium chloride and dry with anhydrous sodium sulfate. Concentrate to obtain a colorless oily product, the crude product yield is 99.1%. 1 H NMR(400MHz,CDCl3)δ7.26(d,J=12.0Hz,1H),6.89(d,J=12.0Hz,1H),5.24(s,2H)3.82- 3.78(m,2H)2.67-2.62(m,2H),1.19(t,J=12.0Hz,3H),0.98-0.94(m,2H),0.01(s,9H).

[0124] Intermediate 4: Synthesis of (2-((5-ethyl-2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)phenoxy)methoxy)ethyl)trimethylsilane Intermediate 3 (280.0 mg, 0.80 mmol), pinacol boronic acid ester (206.1 mg, 0.80 mmol), Pd(dppf)Cl2 (59.2 mg, 0.08 mmol) and KOAc (237.5 mg, 2.40 mmol) are dissolved in 1,4-dioxane (6 ml) and purged with nitrogen three times. The mixture is heated to 100°C and reacted overnight. After completion of the reaction, the mixture is quenched by adding water, extracted with ethyl acetate, and the organic phase is washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The mixture is concentrated and subjected to column chromatography to obtain a colorless oily product with a yield of 56.2%. 1 H NMR(400MHz,CDCl3)δ7.48(d,J=12.0Hz,1H),7.02(d,J=8.0Hz,1H),5.28(s,2H),3.82-3.78(m ,2H),2.89-2.83(m,2H),1.35(s,12H),1.17(t,J=8.0Hz,3H),0.98-0.94(m,2H),0.01(s,9H).

[0125] Intermediate 17: Synthesis of 6-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole Compound 6-iodoindazole (200mg, 0.82mmol) and 5ml of THF are added to the reaction system, and the temperature is lowered to 0℃. At 0℃, NaH (32.8mg (60%), 0.82mmol) is added to the reaction system in batches, and after the addition is completed, the reaction is allowed to proceed at 0℃ for 1 hour. Then, SEMCl (143.5mg, 0.86mmol) is added dropwise to the reaction system, and after the addition is completed, the reaction is allowed to proceed to room temperature and proceed to proceed. After the reaction is completed, water is added to quench the reaction, and EA is added to extract, the solution is separated, and the organic phase is washed with saturated sodium chloride solution and dried with anhydrous sodium sulfate. Concentration and column chromatography are used to obtain 252mg of the product, with a yield of 82.2%. 1H NMR(400MHz,CDCl3)δ8.16(s,1H),8.07(s,1H),8.21(d,J=1.4Hz,1H),7.47-7 .43(m,1H),5.69(s,2H),3.63-3.58(m,2H),0.96-0.91(m,2H),-0.04(s,9H).

[0126] Intermediate 5: Synthesis of 6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl))ethoxy)methyl)-1H-indazole Under N2 atmosphere, intermediate 4 (85 mg, 0.21 mmol), intermediate 17 (80 mg, 0.21 mmol), Pd(dppf)Cl2 (15.6 mg, 0.021 mmol), K3PO4 (136.3 mg, 0.64 mmol), and 1,4-dioxane (2 ml) are added to the reaction system. After the addition is complete, the temperature is raised to 100 °C and the reaction is allowed to proceed overnight. After the reaction is complete, water is added to quench the reaction, and EA is added to extract the reaction, the solution is separated, and the organic phase is washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. Concentration and column chromatography are used to obtain 66.9 mg of a colorless oily product, with a yield of 60.6%. 1 H NMR(400MHz,CDCl3)δ8.14(s,1H),7.69(d,J=8.0Hz,1H),7.61(s,1H),7.15(d,J=8.0Hz,1H),7.05-7.01(m,2H),5.74(s,2H),5.31(s ,2H),3.88-3.84(m,2H),3.70-3.65(m,2H),2.61-2.52(m,2H),1.09(t,J=8.0Hz,3H),1.03-0.96(m,4H),0.01(s,9H),-0.03(s,9H).

[0127] Intermediate 6: Synthesis of 5-ethyl-2-fluoro-4-(1H-indazol-6-yl)phenol Add intermediate 5 (30mg, 0.12mmol), 2ml of methanol, and 1ml of concentrated hydrochloric acid to the reaction system, and after the addition is completed, heat to 60℃ and react. After the reaction is completed, add saturated NaHCO3 solution to adjust pH=7, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 12mg of white solid by column chromatography, the yield is 80.6%. 1 H NMR(400MHz,MeOD)δ8.08(d,J=1.1Hz,1H),7.79(dd,J=0.8Hz,J=8.3Hz,1H),7.42-7.40(m,1H) ,7.08(dd,J=1.4Hz,J=8.3Hz,1H),6.95-6.88(m,2H),2.58-2.51(m,2H),1.06(t,J=8.0Hz3H).

[0128] Intermediate 7: Synthesis of 5-ethyl-2-fluoro-4-(3-iodo-1H-indazol-6-yl)phenol Add intermediate 6 (134 mg, 0.52 mmol), 2 ml of DMF, and KOH (117 mg, 2.08 mmol) to the reaction system, and after the addition is completed, cool to 0 ° C. At 0 ° C, add I2 (132 mg, 0.52 mmol) in DMF (2 ml) dropwise, and after the addition is completed, warm to room temperature and react. After the reaction is completed, add 1 M HCl solution to adjust to pH 7, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 150 mg of white solid by column chromatography, with a yield of 75.5%. 1 H NMR(400MHz,CDCl3)δ7.52(dd,J=0.8Hz,J=8.3Hz,1H),7.35(t,J=1.1Hz,1H),7.15(dd, J=1.3Hz,J=8.4Hz,1H),6.98-6.94(m,2H),2.50(q,J=7.6Hz,2H),1.06(t,J=7.6Hz,3H).

[0129] Intermediate 8: Synthesis of 6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole Add intermediate 7 (180mg, 0.47mmol) and 4ml of DMF to the reaction system. After the addition is complete, cool to 0℃. At 0℃, add NaH (37.6mg (60%), 0.94mmol) in batches, and stir for 1 hour after the addition is complete. Then, add SEMCl (173.4mg, 1.04mmol) dropwise at 0℃, and after the addition is complete, warm to room temperature and react. After the reaction is completed, add water to quench, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 220mg of colorless oily product by column chromatography, the yield is 72.9%. 1 H NMR(400MHz,CDCl3)δ7.52-7.41(m,2H),7.23-7.12(m,2H),7.02-6.97(m,1H),5.73(s,2H),5.30(s,2H),3.88-3.81 (m,2H),3.67-3.55(m,2H),2.56-2.48(m,2H),1.06(t,J=8.0Hz,3H),1.03-0.96(m,4H),0.03(s,9H),-0.07(s,9H).

[0130] Intermediate 9: Synthesis of 6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-3-(trimethylstannyl)-1H-indazole Under N2 atmosphere, add intermediate 8 (20 mg, 0.031 mmol), Sn2Me6 (20.3 mg, 0.062 mmol), Pd(PPh3)4 (3.6 mg, 0.0031 mmol), and 5 ml of dry toluene to the reaction system. After the addition is complete, the temperature is raised to 80 °C and the reaction is continued. After the reaction is completed, add water to quench, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 14.8 mg of colorless oily product by column chromatography, the yield is 70.2%. 1 H NMR(400MHz,CDCl3)δ7.72(d,J=8.0Hz,1H),7.45(s,2H),7.15(d,J=8.0Hz,1H),7 .08(dd,J=4.0Hz,J=8.0Hz,1H),6.99(d,J=12.0Hz,1H),5.77(s,2H),5.31(s,2H) ,3.88-3.84(m,2H),3.60-3.56(m,2H),2.55(q,J=8.0Hz,2H),1.07(t,J=8.0Hz,3 H),1.02-0.98(m,2H),0.90-0.85(m,2H),0.48(s,9H),0.03(s,9H),-0.07(s,9H).

[0131] Intermediate 19: Synthesis of methyl 2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate 1. Intermediate 18: Synthesis of methyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate Add compound 1H-imidazole-4-carboxylate methyl (1g, 7.9mmol), K2CO3 (2.74g, 19.8mmol), 20ml DMF to the reaction system, add SEMCl (1.71g, 10.2mmol) dropwise to the reaction system, and after the dropwise addition is completed, heat the reaction system to 80°C. After the reaction is completed, add water to quench, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 750mg of product by column chromatography, the yield is 37.1%. 1 H NMR (400MHz, CDCl3) δ7.68(s,1H),7.58(s,1H),5.26(s,2H),3.84(s,3H),3.48-3.43(m,2H),0.88-0.83(m,2H),-0.05(s,9H).

[0132] 2. Intermediate 19: Synthesis of methyl 2-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate Add intermediate 18 (4g, 15.6mmol), NIS (7g, 31.1mmol), AIBN (0.26g, 1.58mmol), and 20ml of CHCl3 to the reaction system, and heat the reaction system to 65°C. After the reaction is completed, cool it to room temperature, add 5% sodium thiosulfate aqueous solution to quench the reaction, add DCM to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 3g of product by column chromatography, with a yield of 50.3%. 1 H NMR (400MHz, CDCl3) δ7.80(s,1H),5.26(s,2H),3.89(s,3H),3.58-3.52(m,2H),0.95-0.85(m,2H),-0.01(s,9H).

[0133] Intermediate 10: Synthesis of methyl 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-3-methyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylic acid Under N2 atmosphere, add intermediate 9 (40mg, 0.059mmol), intermediate 19 (22.4mg, 0.059mmol), CuI (2.23mg, 0.012mmol), Pd(PPh3)4 (6.8mg, 0.0059mmol), and 4ml of THF to the reaction system. After the addition is complete, the temperature is raised to 65℃ and the reaction is continued. After the reaction is complete, add water to quench, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 14mg of colorless oily product by column chromatography, the yield is 30.8%. 1 H NMR(400MHz,CDCl3)δ8.57(d,J=8.0Hz,1H),7.92(s,1H),7.45(s,1H),7.25(dd,J=1.2Hz,J =8.4Hz,1H),7.16(d,J=8.0Hz,1H),7.02(d,J=12.0Hz,1H),5.96(s,2H),5.76(s,2H),5.31( s,2H),3.96(s,3H),3.88-3.84(m,2H),3.61-3.57(m,4H),2.53(q,J=8.0Hz,2H),1.05(t,J= 8.0Hz,3H),1.03-0.98(m,2H),0.92-0.87(m,4H),0.03(s,9H),-0.07(s,9H),-0.08(s,9H).

[0134] Intermediate 11: Synthesis of (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanol Under N2 atmosphere, add intermediate 10 (22 mg, 0.028 mmol) and 4 ml of THF to the reaction system, and cool to -78°C. At -78°C, add DIBAL-H (0.038 ml, 1.5 mol / L, 0.057 mmol). After the dropwise addition is completed, warm to room temperature and react. After the reaction is completed, cool to 0°C, add water to quench, pass through diatomaceous earth, rinse with EA, extract the filtrate with EA, separate the liquid, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 17 mg of colorless oily product by column chromatography, the yield is 81.8%. 1 H NMR(400MHz,CDCl3)δ8.48(d,J=8.0Hz,1H),7.46(s,1H),7.23(d,J=8.0Hz,1H),7.18 -7.15(m,2H),7.02(d,J=12.0Hz,1H),5.92(s,2H),5.76(s,2H),5.32(s,2H),4.75(s ,2H),3.88-3.84(m,2H),3.62-3.55(m,4H),2.54(q,J=8.0Hz,2H),1.06(t,J=8.0Hz, 3H),1.04-0.98(m,2H),0.92-0.86(m,4H),0.04(s,9H),-0.07(s,9H),-0.08(s,9H).

[0135] Intermediate 12: Synthesis of 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-formaldehyde Add intermediate 11 (12mg, 0.016mmol), 4ml of CHCl3, MnO2 (57.4mg, 0.66mmol) to the reaction system, heat to 60℃ and react. After the reaction is completed, cool to room temperature, pass through diatomaceous earth, wash with DCM, wash the filtrate with saturated sodium chloride solution, dry with anhydrous sodium sulfate. Concentrate and obtain 10mg of colorless oily product by column chromatography, yield 84.4%. 1 H NMR(400MHz,CDCl3)δ10.04(s,1H),8.59(d,J=8.0Hz,1H),7.95(s,1H),7.48(s,1H),7.29(d d,J=4.0Hz,J=8.0Hz,1H),7.17(d,J=8.0Hz,1H),7.02(d,J=12.0Hz,1H),6.03(s,2H),5.77( s,2H),5.32(s,2H),3.88-3.84(m,2H),3.64-3.59(m,4H),2.55(q,J=8.0Hz,2H),1.06(t,J= 8.0Hz,3H),1.04-0.99(m,2H),0.93-0.88(m,4H),0.04(s,9H),-0.06(s,9H),-0.07(s,9H).

[0136] Intermediate 13: Synthesis of 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxaldehyde oxime Add intermediate 12 (10mg, 0.016mmol), TEA (1.68mg, 0.017mmol), 2ml DCM to the reaction system, cool to 0℃, add hydroxylamine hydrochloride (1.15mg, 0.017mmol) in batches, and after the addition is complete, warm to room temperature and react. After the reaction is completed, add water to quench, add DCM to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate to obtain 7mg of colorless oily product, which can be used directly in the next step, with a yield of 68.4%.

[0137] Intermediate 14: Synthesis of 4-(3-(4-(aminomethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol Add intermediate 13 (10 mg, 0.013 mmol), Pd / C (2 mg), 2 ml of MeOH, and catalytic amount of HCl to the reaction system, replace with H2 three times, and react at room temperature (H2 pressure is 1 atm). After the reaction is completed, pass the reaction system through diatomaceous earth, and concentrate the filtrate. Obtain 5 mg of a colorless oily product by column chromatography, with a yield of 63.0%. 1 H NMR(400MHz,CDCl3)δ8.39(d,J=8.0Hz,1H),7.42(s,1H),7.13-7.10(m,2H),6.96-6.91(m,2H,),5.89(s,2H),5.74(s,2H),4 .01(s,2H),3.61-3.55(m,4H),2.46(q,J=8.0Hz,2H),1.00(t,J=8.0Hz,3H),0.91-0.86(m,4H),-0.08(s,9H),-0.09(s,9H).

[0138] Intermediate 21: Synthesis of 5-(piperidin-1-yl)pyrazine-2-carboxylic acid 1. Intermediate 20: Synthesis of methyl 5-(piperidin-1-yl)pyrazine-2-carboxylate Methyl 5-chloro-pyrazine-2-carboxylate (1.72 g, 10 mmol) was dissolved in 10 ml of DMF, N,N-diisopropylethylamine (4.3 ml, 25.0 mmol) and piperidine hydrochloride (1.45 g, 12.0 mmol) were added, and the mixture was stirred at room temperature overnight. With vigorous stirring, water was added to precipitate a solid, which was filtered, and the filter cake was washed with water and dried to obtain intermediate 20, with a yield of 80.0%.

[0139] 2. Intermediate 21: Synthesis of 5-(piperidin-1-yl)pyrazine-2-carboxylic acid Intermediate 20 (430mg, 1.95mmol) was dissolved in 20ml of tetrahydrofuran and 20ml of water, lithium hydroxide (163mg, 3.88mmol) was added, and the mixture was reacted at room temperature for 4 hours, concentrated under reduced pressure to remove tetrahydrofuran, and adjusted to pH=4 with 1N HCl to precipitate solids, filtered, and the filter cake was washed with water and dried to obtain intermediate 21, with a yield of 91.5%. 1 H NMR (400MHz, CDCl3) δ8.84(s,1H),8.02(s,1H),3.76-3.73(m,4H),1.78-1.65(m,6H).

[0140] Intermediate 15: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-5-(piperidin-1-yl)pyrazine-2-carboxamide Add intermediate 21 (10.4 mg, 0.050 mmol), HATU (22.9 mg, 0.060 mmol), DIPEA (12.9 mg, 0.10 mmol), and 2 ml of DMF to the reaction system and react at room temperature for 1 hour. The reaction system is cooled to 0°C, and a solution of compound 14 (30 mg, 0.049 mmol) in DMF (0.5 ml) is added dropwise. After the addition is completed, the temperature is raised to room temperature and the reaction is continued. After the reaction is completed, water is added to quench the reaction, and EA is added to extract the reaction, the solution is separated, and the organic phase is washed with saturated sodium chloride solution and dried with anhydrous sodium sulfate. The mixture is concentrated and subjected to column chromatography to obtain 27 mg of a colorless oily product, with a yield of 67.2%. 1H NMR(400MHz,CDCl3)δ8.86(d,J=1.3Hz,1H),8.50(d,J=8.0Hz,1H),7.95(d,J=1.4Hz, 1H),7.44(s,1H),7.22-7.20(m,2H),7.00-6.94(m,2H),5.89(s,2H),5.75(s,2H),4. 71(d,J=5.7Hz,2H),3.69-3.66(m,4H),3.61-3.55(m,4H),2.51(q,J=8.0Hz,2H),1.7 1-1.65(m,6H),1.04(t,J=8.0Hz,3H),0.91-0.86(m,4H),-0.08(s,9H),-0.09(s,9H).

[0141] Synthesis of Compound 16 (i.e., MDI-3): N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-(piperidin-1-yl)pyrazine-2-carboxamide Compound 15 (30 mg, 0.037 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid are added to the reaction system, and after the addition is completed, the temperature is raised to 60 ° C. and the reaction is continued. After the reaction is completed, saturated NaHCO3 is added to adjust the pH to 7, EA is added to extract, the solution is separated, the organic phase is washed with saturated sodium chloride solution, and dried with anhydrous sodium sulfate. Concentration is performed and 14 mg of a white solid is obtained by thin layer chromatography, with a yield of 69.2%. 1 H NMR(400MHz,MeOD)δ8.70(d,J=1.4Hz,1H),8.30(d,J=8.0Hz,1H),8.21(d,J=1.4Hz,1H),7.43(s,1H),7.19-7.17(m,2H) ),6.98-6.90(m,2H),4.67(s,2H),3.78-3.75(m,4H),2.56(q,J=8.0Hz,2H),1.79-1.67(m,6H),1.08(t,J=8.0Hz,3H).

[0142] Example 2: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propionamide (MDI-301) [ka]

[0143] Synthesis scheme of MDI-301: [ka]

[0144] Synthesis method: Synthesis of intermediate MDI-301-1: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)propionamide Add intermediate 14 (30mg, 0.049mmol), DIPEA (7.6mg, 0.059mmol) and 5ml of DCM to the reaction system. Lower the temperature of the reaction system to 0℃, add propionyl chloride (4.5mg, 0.049mmol) dropwise, and after the dropwise addition is completed, warm it up to room temperature and react. After the reaction is completed, add water to quench, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution and dry with anhydrous sodium sulfate. Concentrate and obtain 18mg of colorless oily product by column chromatography, the yield is 55.0%. 1 H NMR(400MHz,CDCl3)δ8.41(d,J=8.0Hz,1H),7.45(s,1H),7.21(d,J=8.0Hz,1H) ,7.15(s,1H),6.96(t,J=10.0Hz,2H),5.88(s,2H),5.75(s,2H),4.50(d,J=8.0 Hz,2H),3.62-3.54(m,4H),2.54-2.48(m,2H),2.30-2.20(m,2H),1.20(t,J=8. 0Hz, 3H), 1.05 (t, J=8.0Hz, 3H), 0.92-0.86 (m, 4H), -0.07 (s, 9H), -0.09 (s, 9H).

[0145] Synthesis of compound MDI-301: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propionamide The reaction system is added with intermediate MDI-301-1 (18 mg, 0.027 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid, and after the addition is completed, the temperature is raised to 50° C. and the reaction is continued. After 6 hours of reaction, the temperature is lowered to room temperature, and the reaction solvent is evaporated by concentrating under reduced pressure, and then 4 ml of methanol and 0.5 ml of aqueous ammonia are added, and the residue after concentration is subjected to thin layer chromatography to obtain 3 mg of a white solid, with a yield of 27.3%. 1 H NMR(400MHz,MeOD)δ8.27(d,J=8.0Hz,1H),7.40(s,1H),7.15(d,J=8.0Hz,1H),7.10(s,1H),6.91(dd,J=12.0Hz,J=2 0.0Hz,2H),4.44(s,2H),2.53(q,J=8.0Hz,2H),2.87(q,J=8.0Hz,2H),1.16(t,J=8.0Hz,3H),1.06(t,J=8.0Hz,3H).

[0146] Example 3: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanecarboxamide (MDI-302) [ka]

[0147] Synthesis scheme of MDI-302: [ka]

[0148] Synthesis method: Synthesis of intermediate MDI-302-1: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)cyclopropanecarboxamide Add intermediate 14 (30mg, 0.049mmol), DIPEA (7.6mg, 0.059mmol) and 5ml of DCM to the reaction system. The reaction system is cooled to 0℃, and cyclopropylcarbonyl chloride (5.1mg, 0.049mmol) is added dropwise. After the addition is completed, the temperature is raised to room temperature and the reaction is continued. After the reaction is completed, water is added to quench the reaction, and EA is added to extract the reaction. The solution is separated, and the organic phase is washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The mixture is concentrated and subjected to column chromatography to obtain 22mg of a colorless oily product, with a yield of 66.1%. 1 H NMR(400MHz,CDCl3)δ8.42(d,J=8.0Hz,1H),7.44(s,1H),7.20(d,,J=8.0Hz,1H),7 .15(s,1H),6.9(t,J=12.0Hz,2H),5.88(s,2H),5.75(s,2H),4.52(d,J=8.0Hz,2H), 3.62-3.54(m,4H),2.53-2.47(m,2H),1.75-1.68(m,1H),1.06(t,J=8.0Hz,3H),1. 02-1.00(m,2H),0.91-0.87(m,4H),0.76-0.72(m,2H),-0.07(s,9H),-0.09(s,9H).

[0149] Synthesis of compound MDI-302: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanecarboxamide Add intermediate MDI-302-1 (20mg, 0.029mmol), 4ml MeOH, 2ml concentrated hydrochloric acid to the reaction system, and after the addition is completed, heat to 50℃ and react. After reacting for 6 hours, cool to room temperature, evaporate the reaction solvent by concentrating under reduced pressure, then add 4ml methanol and 0.5ml ammonia water, and perform thin layer chromatography on the residue after concentration to obtain 8.5mg of white solid, with a yield of 69.9%. 1H NMR(400MHz,MeOD)δ8.28(d,J=8.0Hz1H),7.40(s,1H),7.15(d,J=8.0Hz,1H),7.10(s,1H),6.91(dd,J=12.0Hz,J=20.0Hz ,2H),4.45(s,2H),2.54(q,J=8.0Hz,2H),1.67-1.61(m,1H),1.06(t,J=8.0Hz,3H),0.92-0.85(m,2H),0.79-0.75(m,2H).

[0150] Example 4: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)isobutyramide (MDI-303) [ka]

[0151] Synthesis scheme of MDI-303: [ka]

[0152] Synthesis method: Synthesis of intermediate MDI-303-1: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)isobutyramide Add intermediate 14 (20mg, 0.033mmol), DIPEA (5.1mg, 0.039mmol) and 5ml of DCM to the reaction system. Cool the reaction system to 0℃, add isobutyryl chloride (3.48mg, 0.033mmol) dropwise, and after the addition is complete, warm to room temperature and react. After the reaction is completed, add water to quench, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution and dry with anhydrous sodium sulfate. Concentrate and obtain 14mg of colorless oily product by column chromatography, the yield is 62.3%. 1H NMR(400MHz,CDCl3)δ8.38(d,J=8.0Hz,1H),7.44(s,1H),7.18(d,J=8.0Hz,1H ),7.15(s,1H),6.96-6.92(m,2H),5.87(s,2H),5.75(s,2H),4.50(d,J=8.0Hz, 2H),3.62-3.54(m,4H),2.52-2.46(m,2H),2.44-2.39(m,1H),1.19(d,J=4.0Hz ,6H),1.03(t,J=8.0Hz,3H),0.92-0.86(m,4.0H),-0.07(s,9H),-0.09(s,9H).

[0153] Synthesis of compound MDI-303: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)isobutyramide The reaction system is added with intermediate MDI-303-1 (14 mg, 0.021 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid. After the addition is completed, the solution is heated to 50° C. and reacted. After reacting for 6 hours, the temperature is lowered to room temperature, and the reaction solvent is evaporated by concentrating under reduced pressure. Then, 4 ml of methanol and 0.5 ml of aqueous ammonia are added, and the residue after concentration is subjected to thin layer chromatography to obtain 4.9 mg of a white solid, with a yield of 56.6%. 1 H NMR(400MHz,MeOD)δ8.29(d,J=8.0Hz,1H),7.43(s,1H,),7.17(dd,J=4.0Hz,J=8.0Hz,1H),7.11(s,1H),6.93 (dd,J=12.0Hz,J=20.0Hz,2H),4.46(s,2H),2.68-2.50(m,3H),1.17(d,J=4.0Hz,6H),1.08(t,J=8.0Hz,3H).

[0154] Example 5: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methanesulfonamide (MDI-304) [ka]

[0155] Synthesis scheme of MDI-304: [ka]

[0156] Synthesis method: Synthesis of intermediate MDI-304-1: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)methanesulfonamide Add intermediate 14 (30mg, 0.049mmol), DIPEA (7.6mg, 0.059mmol) and 5ml of DCM to the reaction system. The reaction system is cooled to 0℃, methanesulfonyl chloride (5.61mg, 0.049mmol) is added dropwise, and after the addition is completed, the temperature is raised to room temperature and the reaction is continued. After the reaction is completed, water is added to quench the reaction, EA is added to extract, the solution is separated, the organic phase is washed with saturated sodium chloride solution and dried with anhydrous sodium sulfate. Concentrate and obtain 12mg of colorless oily product by column chromatography, the yield is 35.5%. 1 H NMR(400MHz,CDCl3)δ8.40(d,J=8.0Hz,1H),7.46(s,1H),7.23(d,J=8.0Hz,1H),7.19(s,1H),7.00-6.95(m,2H),5.91(s,2H),5.75( s,2H),4.41(d,J=4.0Hz,2H),2.97(s,3H),2.55-2.49(m,2H),1.06(t,J=8.0Hz,3H),0.92-0.86(m,4H),-0.07(s,9H),-0.09(s,9H).

[0157] Synthesis of compound MDI-304: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methanesulfonamide The intermediate MDI-304-1 (12 mg, 0.017 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid are added to the reaction system, and after the addition is completed, the solution is heated to 50°C and reacted. After reacting for 6 hours, the temperature is lowered to room temperature, and the reaction solvent is evaporated by concentrating under reduced pressure, and then 4 ml of methanol and 0.5 ml of aqueous ammonia are added, and the residue after concentration is subjected to thin layer column chromatography to obtain 3.0 mg of a white solid, with a yield of 40.2%. 1 H NMR(400MHz,MeOD)δ8.21(d,J=8.0Hz,1H),7.43(s,1H,),7.21-7.17(m,2H),6.93(dd,J=12. 0Hz,J=20.0Hz,2H),4.37(s,2H),2.97(s,3H),2.56(q,J=8.0Hz,2H),1.08(t,J=8.0Hz,3H).

[0158] Example 6: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-morpholinopyrazine-2-carboxamide (MDI-305) [ka]

[0159] Synthesis scheme of MDI-305: [ka]

[0160] Synthesis method: Synthesis of intermediate MDI-305-1: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-5-morpholinopyrazine-2-carboxamide Compound 5-(4-morpholinyl)-2-pyrazine carboxylic acid (6.84 mg, 0.033 mmol), HATU (13.05 mg, 0.034 mmol), DIPEA (5.06 mg, 0.039 mmol), and 5 ml of DMF are added to the reaction system, and the reaction is allowed to proceed at room temperature for 1 hour. The reaction system is cooled to 0°C, and a solution of compound 14 (20 mg, 0.033 mmol) in DMF (2.0 ml) is added dropwise. After the addition is completed, the reaction is allowed to proceed by raising the temperature to room temperature. After the reaction is completed, water is added to quench the reaction, and EA is added to extract the reaction, the solution is separated, and the organic phase is washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. The reaction is concentrated and 14 mg of a colorless oily product is obtained by column chromatography, with a yield of 52.9%. 1 H NMR(400MHz,CDCl3)δ8.91(s,1H),8.50(d,J=8.0Hz,1H),7.95(s,1H),7.44(s,1 H),7.22-7.20(m,2H),7.00-6.95(m,2H),5.90(s,2H),5.75(s,2H),4.71(d,J=8 .0Hz,2H),3.83-3.81(m,4H),3.68-3.66(m,4H),3.62-3.55(m,4H),2.51(q,J=8 .0Hz,2H),1.05(t,J=8.0Hz,3H),0.91-0.86(m,4H),-0.07(s,9H),-0.09(s,9H).

[0161] Synthesis of compound MDI-305: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-morpholinopyrazine-2-carboxamide The reaction system is added with intermediate MDI-305-1 (14 mg, 0.017 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid, and after the addition is completed, the temperature is raised to 50° C. and the reaction is allowed to proceed. After the reaction is allowed to proceed for 6 hours, the temperature is lowered to room temperature, and the reaction solvent is evaporated by concentrating under reduced pressure, and then 4 ml of methanol and 0.5 ml of aqueous ammonia are added, and the residue after concentration is subjected to thin layer chromatography to obtain 3.9 g of a white solid, with a yield of 41.2%. 1H NMR(400MHz,MeOD)δ8.73(s,1H),8.28(d,J=8.0Hz,1H),8.20(s,1H),7.40(s,1H),7.17-7.14(m,2H),6.95-6 .87(m,2H),4.65(s,2H),3.80-3.77(m,4H),3.73-3.70(m,4H),2.53(q,J=8.0Hz,2H),1.06(t,J=8.0Hz,3H).

[0162] Example 7: (S)-1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidin-3-ol (MDI-306) [ka]

[0163] Synthesis scheme of MDI-306: [ka]

[0164] Synthesis method: Intermediate MDI-306-1: Synthesis of (S)-1-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)pyrrolidin-3-ol Add (s)-1-N-tert-butoxycarbonyl-3-hydroxypyrrolidine (9.1 mg, 0.049 mmol), 2 ml of DCM, 2 ml of trifluoroacetic acid to the reaction system, and stir at room temperature for 30 minutes after the addition is complete. After the reaction is completed, concentrate the reaction system, add 5 ml of 1,2-dichloroethane, intermediate 12 (30 mg, 0.041 mmol) after concentration, and stir at room temperature for 30 minutes after the addition is complete, then add sodium triacetoxyborohydride (17.08 mg, 0.081 mmol) and react at room temperature. After the reaction is completed, add water to quench, add DCM to extract, wash the organic phase with saturated sodium chloride, dry with sodium sulfate, concentrate, and separate by thin layer chromatography to obtain 20 mg of product, with a yield of 60.8%. 1 H NMR(400MHz,CDCl3)δ8.44(d,J=8.0Hz,1H),7.45(s,1H),7.24-7.21(m,2H),7.15(d,J=8.0Hz,1H),7.0(d,J=12.0 Hz,1H),5.91(s,2H),5.75(s,2H),5.32(s,2H),4.44-4.39(m,1H),3.92-3.84(m,4H),3.64-3.55(m,4H),3.29-3.1 9(m,1H),3.12-3.07(m,1H),2.96-2.88(m,1H),2.78-2.66(m,1H),2.57-2.51(m,2H),2.24-2.20(m,1H),1.91-1. 87(m,1H),1.05(t,J=8.0Hz,3H),,1.03-0.98(m,2H),0.92-0.86(m,4H),0.03(s,9H),-0.07(s,9H),-0.09(s,9H).

[0165] Synthesis of compound MDI-306: (S)-1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidin-3-ol The reaction system is added with intermediate MDI-306-1 (20 mg, 0.025 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid. After the addition is completed, the solution is heated to 50° C. and reacted. After reacting for 6 hours, the temperature is lowered to room temperature, and the reaction solvent is evaporated by concentrating under reduced pressure. Then, 4 ml of methanol and 0.5 ml of aqueous ammonia are added, and the residue after concentration is subjected to thin layer chromatography to obtain 6.2 mg of a white solid, with a yield of 59.7%. 1 H NMR(400MHz,MeOD)δ8.31(d,J=8.0Hz,1H),7.43(s,1H,),7.18-7.16(m,2H),6.97-6.89(m,2H),4.44-4.39(m,1H),3.90-3.82 (m,2H),3.01-2.95(m,2H),2.77-2.74(m,2H),2.58-2.53(m,2H),2.25-2.16(m,1H),1.84-1.78(m,1H),1.08(t,J=8.0Hz,3H).

[0166] Example 9: 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidin-4-ol (Ex-9) [ka]

[0167] Synthesis scheme of compound Ex-9: [ka]

[0168] Synthesis method: Synthesis of compound Ex-9: 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidin-4-ol 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (30 mg, 0.04 mmol) is dissolved in DCM, piperidin-4-ol (4.9 mg, 0.05 mmol) is added to the solution, and the reaction is allowed to proceed at room temperature for 0.5 hours. Sodium triacetoxyborohydride (17.2 mg, 0.08 mmol) is added to the reaction solution, and the reaction is allowed to proceed at room temperature for 1 hour. Water is added to the reaction solution. The reaction solution was extracted twice with DCM, the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated, and purified by silica gel plate. The resulting product was dissolved in 2ml of methanol and 1ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 3ml of methanol, added with 0.5ml of aqueous ammonia, concentrated, and purified by separation plate to obtain 6mg of final product, with a yield of 32.8%. 1 H NMR(400MHz,MeOD)δ8.33(d,J=12.0Hz,1H),7.44(s,1H),7.32(s,1H),7.18(d,J=8.0Hz,1H),6.90-6.97(m,2H),4.01-4.08(m,2H),3. 81-3.86(m,1H),3.23-3.30(m,2H),2.78-2.92(m,2H),2.53-2.59(m,2H),1.98-2.04(m,2H),1.72-1.80(m,2H),1.08(t,J=8.0Hz,3H).

[0169] Example 10: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-N-methylcyclopropanecarboxamide (Ex-10) [ka]

[0170] Synthesis scheme of compound Ex-10: [ka]

[0171] Synthesis method: Synthesis of compound Ex-10: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-N-methylcyclopropanecarboxamide 1-(2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-N-methylmethylamine (20 mg, 0.03 mmol) was dissolved in DCM, triethylamine (5.3 mg, 0.05 mmol) was added, and the temperature was lowered to 0° C., and cyclopropanecarbonyl chloride (3 0.3mg, 0.03mmol) was added dropwise and reacted at room temperature for 1 hour. Water was added to the reaction solution and extracted with DCM twice. The organic phases were combined, washed with saturated saline, dried with anhydrous sodium sulfate, concentrated and purified by silica gel plate. The obtained product was dissolved in 2ml of methanol and 1ml of concentrated hydrochloric acid, reacted at 50℃ for 6 hours, concentrated, dissolved in 3ml of methanol, added with 0.5ml of ammonia water, concentrated and purified by separation plate to obtain 4mg of final product, the yield is 34.9%. 1 H NMR(400MHz,DMSO)δ13.29(s,1H),12.62(s,1H),9.86(s,1H),8.34(d,J=8.0Hz,1H),7.40(s,1H),7.13(d,J=8.0Hz,2H),7.04(d,J=12.0Hz,1H) ),6.92(d,J=8.0Hz,1H),4.51-4.67(m,2H),3.17-3.23(s,3H),2.46-2. 48(m,2H),1.99-2.01(m,1H),1.02(t,J=8.0Hz,3H),0.76-0.87(m,4H). LC-MS m / z(ESI)[M+H] + :C 24 H 25 The calculated value for FN5O2 is 434.2 and the measured value is 434.2.

[0172] Example 11: 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidine-4-nitrile (Ex-11) [ka]

[0173] Synthesis scheme of compound Ex-11: [ka]

[0174] Synthesis method: Intermediate 11-1: Synthesis of 1-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)piperidine-4-nitrile 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (25.0 mg, 0.03 mmol) was added to 5 ml of dry dichloromethane, 4-cyanopiperidine (5.6 mg, 0.05 mmol) was added, and the mixture was reacted at room temperature for 30 minutes, and sodium triacetoxyborohydride (10.7 mg, 0.05 mmol) was added, and the mixture was reacted at room temperature for 1 hour. The reaction mixture was added with water, extracted twice with dichloromethane, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 24.2 mg of intermediate 11-1, the yield being 86.0%.

[0175] Synthesis of compound Ex-11: 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidine-4-nitrile 11-1 (24.2 mg, 0.03 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified on a silica gel plate to obtain 3.4 mg of the final product, with a yield of 26.4%. 1 H NMR(400MHz,MeOD)δ8.30(dd,J=4.0Hz,J=8.0Hz,1H),7.43(d,J=4.0Hz,1H),7.19-7.16(m,2H),6.95(dd,J=8.0Hz,J=20. 0Hz,2H),3.75(s,2H),2.89-2.86(m,3H),2.59-2.53(m,4H),2.06-2.03(m,2H),1.97-1.86(m,2H),1.08(t,J=8.0Hz,3H).

[0176] Example 12: 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidine-3-carbonitrile (Ex-12) [ka]

[0177] Synthesis scheme of compound Ex-12: [ka]

[0178] Synthesis method: Intermediate 12-1: Synthesis of 1-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)pyrrolidine-3-carbonitrile The intermediate 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-3-yl)-1-(((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (30.0 mg, 0.04 mmol) was dissolved in 5 ml of dichloromethane, pyrrolidine-3-nitrile (5.1 mg, 0.05 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours. Sodium triacetoxyborohydride (17.0 mg, 0.08 mmol) was then added to the reaction mixture, and the mixture was stirred at room temperature for 2 hours. The reaction was quenched by adding a small amount of water, the solvent was removed using a vacuum pump, and the mixture was purified by a preparative silica gel plate to give 21 mg of intermediate 12-1, with a yield of 56.9%.

[0179] Synthesis of compound Ex-12: 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidine-3-carbonitrile 12-1 (20.0 mg, 0.02 mmol) was dissolved in 2 ml of methanol solution, 1 ml of concentrated hydrochloric acid was added, and the mixture was reacted at 50° C. for 6 hours. The reaction solution was concentrated, dissolved in 3 ml of methanol, 0.5 ml of aqueous ammonia was added, concentrated, and purified by a silica gel plate for separation to obtain 3 mg of the final product, with a yield of 28.6%. 1 H NMR(400MHz,DMSO)δ13.27(s,1H),12.58(s,1H),9.87(s,1H),8.34(d,J=8.4Hz,1H) ,7.39(s,1H),7.13(d,J=7.5Hz,2H),7.04(d,J=11.9Hz,1H),6.92(d,J=9.1Hz,1H),3 .61(s,2H),3.17-3.18(m,1H),2.98-3.11(m,1H),2.75-2.82(m,1H),2.62-2.72(m, 1H), 2.55-2.61 (m, 1H), 2.43-2.49 (m, 2H), 1.96-2.04 (m, 2H), 1.02 (t, J=7.5Hz, 3H).

[0180] Example 13: 5-Ethyl-2-fluoro-4-(3-(4-(morpholinomethyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol (Ex-13) [ka]

[0181] Synthesis scheme of compound Ex-13: [ka]

[0182] Synthesis method: Synthesis of compound Ex-13: 5-ethyl-2-fluoro-4-(3-(4-(morpholinomethyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (30.0 mg, 0.04 mmol) was dissolved in DCM, morpholine (4.4 mg, 0.05 mmol) was added, and the reaction was allowed to proceed at room temperature for 0.5 hours. The reaction solution was then treated with sodium triacetoxyborohydride. (17.2mg, 0.08mmol) was added and reacted at room temperature for 1 hour, water was added to the reaction solution, extracted twice with DCM, the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified, the resulting product was dissolved in 2ml of methanol and 1ml of concentrated hydrochloric acid, reacted at 50℃ for 6 hours, concentrated, dissolved in 3ml of methanol, added with 0.5ml of aqueous ammonia, concentrated and purified by preparative silica gel plate to obtain 8mg of the final product, the yield is 46.9%. 1H NMR(400MHz,DMSO)δ13.23(s,1H),12.55(d,J=20.0Hz,1H),9.85(s,1H),8.34(d,J=8.0Hz,1H),7.39(s,1H),7.10-7.14(m,1H),6.95- 7.05(m,2H),6.92(t,J=8.0Hz,1H),3.59(t,J=4Hz,4H),3.49-3.55(m,2H),2.49-2.50(m,2H),2.42-2.48(m,4H),1.02(t,J=8Hz,3H).

[0183] Example 14: 5-Ethyl-2-fluoro-4-(3-(4-((pyridin-3-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol (Ex-14) [ka]

[0184] Synthesis scheme of compound Ex-14: [ka]

[0185] Synthesis method: Intermediate 14-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)pyridin-3-amine 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (30.0 mg, 0.04 mmol) was dissolved in 5 ml of toluene, 3-aminopyridine (5.6 mg, 0.06 mmol) and one drop of glacial acetic acid were added, the mixture was heated to 90°C, reacted for 24 hours, cooled to room temperature, and sodium triacetoxyborohydride (12.7 mg, 0.06 mmol) was added and reacted at room temperature for 1 hour. The reaction mixture was added with water, extracted twice with ethyl acetate, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 23 mg of intermediate 14-1, the yield being 69.3%.

[0186] Synthesis of compound Ex-14: 5-ethyl-2-fluoro-4-(3-(4-((pyridin-3-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol 14-1 (23.0 mg, 0.03 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified by preparative silica gel plate to obtain 7.1 mg of the final product, with a yield of 59.0%. 1 H NMR(400MHz,MeOD)δ8.29(dd,J=4.0Hz,J=12.0Hz,1H),8.05(d,J=4.0Hz,1H),7.80(d,J=4.0Hz,1H),7.42(d,J=4.0H) z,1H),7.20-7.14(m,4H),6.95(dd,J=12.0Hz,J=20.0Hz,2H),4.44(s,2H),2.59-2.53(m,2H),1.08(t,J=8.0Hz,3H).

[0187] Example 15: 5-Ethyl-2-fluoro-4-(3-(4-(((1-methyl-1H-pyrazol-4-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol (Ex-15) [ka]

[0188] Synthesis scheme of compound Ex-15: [ka]

[0189] Synthesis method: Intermediate 15-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-1-methyl-1H-pyrazol-4-amine 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (30.0 mg, 0.04 mmol) was dissolved in 5 ml of toluene, 1-methyl-1H-pyrazol-4-amine (5.9 mg, 0.06 mmol) and one drop of glacial acetic acid were added, and the mixture was heated to 90° C. and reacted for 24 hours. The mixture was cooled to room temperature, and sodium triacetoxyborohydride (12.7 mg, 0.06 mmol) was added and reacted at room temperature for 1 hour. The reaction mixture was added with water and extracted twice with ethyl acetate, the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 22.9 mg of intermediate 15-1, the yield was 68.8%.

[0190] Synthesis of compound Ex-15: 5-ethyl-2-fluoro-4-(3-(4-(((1-methyl-1H-pyrazol-4-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol 15-1 (22.9 mg, 0.03 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified by preparative silica gel plate to obtain 5.4 mg of the final product, with a yield of 45.0%. 1 H NMR(400MHz,MeOD)δ8.29(dd,J=4.0Hz,J=12.0Hz,1H),7.42(d,J=4.0Hz,1H),7.25(d,J=4.0Hz,1H),7.21(d,J=4.0Hz,1H),7.17(dd,J=4 .0Hz,J=8.0Hz,1H),7.13(s,1H),6.94(dd,J=12.0Hz,J=20.0Hz,2H),4.21(s,2H),3.80(s,3H),2.59-2.53(m,2H),1.08(t,J=8.0Hz,3H).

[0191] Example 16: 3-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-(2-hydroxyethyl)-1-methylurea (Ex-16) [ka]

[0192] Synthesis scheme of compound Ex-16: [ka]

[0193] Synthesis of compound Ex-16: 3-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-(2-hydroxyethyl)-1-methylurea Triphosgene (11.1 mg, 0.04 mmol) was dissolved in DCM, and the temperature was lowered to 0° C. A DCM solution of (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (25.0 mg, 0.03 mmol) was added dropwise to the solution, and the reaction was allowed to proceed at 0° C. for 5 minutes. Triethylamine (10.2 mg, 0.10 mmol) was then slowly added to the reaction solution. Dropwise, react at 0°C for 0.5 hours, add 2-(methylamino)ethan-1-ol (3.8mg, 0.05mmol) to the reaction solution, react at room temperature for 1 hour, add water to the reaction solution, extract with DCM twice, combine the organic phase, wash with saturated saline, dry with anhydrous sodium sulfate, concentrate, purify, dissolve the obtained product in 2ml of methanol and 1ml of concentrated hydrochloric acid, react at 50°C for 6 hours, concentrate, dissolve in 3ml of methanol, add 0.5ml of ammonia water, concentrate, purify by silica gel plate for separation, obtain 7mg of final product, yield is 45.9%. 1 H NMR(400MHz,MeOD)δ8.28(d,J=8.0Hz,1H),7.42(s,1H),7.17(d,J=8.0Hz,1H),7.10(s,1H),6.89-6.97(m,2H),4 .44(s,2H),3.71(t,J=6.0Hz,2H),3.45(t,J=6.0Hz,2H),3.01(s,3H),2.53-2.59(m,2H),1.08(t,J=8.0Hz,3H).

[0194] Example 17: 4-(3-(4-(((cyclopropylmethyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol (Ex-17) [ka]

[0195] Synthesis scheme of compound Ex-17: [ka]

[0196] Synthesis method: Synthesis of compound Ex-17: 4-(3-(4-(((cyclopropylmethyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (30.0 mg, 0.04 mmol) and cyclopropylmethylamine (4.2 mg, 0.06 mmol) were dissolved in DCM and reacted at room temperature for 0.5 hours. Sodium triacetoxyborohydride was added to the reaction solution. Add 16.4mg (0.06mmol) and react at room temperature for 1.5 hours, add water to the reaction solution, extract with DCM twice, combine the organic phases, wash with saturated saline, dry with anhydrous sodium sulfate, concentrate, purify, dissolve the product in 2ml of methanol, add 1ml of concentrated hydrochloric acid, react at 50℃ for 6 hours, concentrate, dissolve in 3ml of methanol, add 0.5ml of aqueous ammonia, concentrate, purify by silica gel plate for separation to obtain 6.4mg of final product, yield 39.0%. 1 H NMR(400MHz,MeOD)δ8.35(d,J=8Hz,1H),7.45(s,1H),7.33(s,1H),7.22-7.17(m,1H),6.99-6.88(m,2H),4.19(s,2H) ,2.91(d,J=8Hz,2H),2.62-2.51(m,2H),1.18-1.11(m,1H),1.08(t,J=8Hz,3H),0.74-0.67(m,2H),0.42-0.35(m,2H).

[0197] Example 18: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanesulfonamide (Ex-18) [ka]

[0198] Synthesis scheme of compound Ex-18: [ka]

[0199] Synthesis method: Intermediate 18-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)cyclopropanesulfonamide Add (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (30.0mg, 0.04mmol), TEA (13.1mg, 0.12mmol), and 5ml of DCM to the reaction system. The reaction system is cooled to 0°C, and cyclopropanesulfonyl chloride (7.4mg, 0.05mmol) is added dropwise. After the addition is complete, the reaction is allowed to proceed at room temperature for 1 hour. After the reaction was completed, water was added to quench, DCM was added to extract, the solution was separated, and the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated and purified to obtain 24 mg of colorless oily product, the yield is 70.0%.

[0200] Synthesis of compound Ex-18: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanesulfonamide Add intermediate 18-1 (24 mg, 0.03 mmol), 4 ml of methanol, and 2 ml of concentrated hydrochloric acid to the reaction system, and heat the reaction to 50° C. Allow to react for 6 hours, concentrate, then add 4 ml of methanol and 0.5 ml of aqueous ammonia, concentrate, and purify by preparative silica gel plate to obtain 8 mg of white solid, yield 61.3%. LC-MS m / z(ESI)[M+H] + :C 22 H 23 The calculated value for FN5O3S is 456.1 and the measured value is 456.1.

[0201] Example 19: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)ethanesulfonamide (Ex-19) [ka]

[0202] Synthesis scheme of compound Ex-19: [ka]

[0203] Synthesis method: Intermediate 19-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)ethanesulfonamide (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (30.0 mg, 0.04 mmol), TEA (12.3 mg, 0.12 mmol), and 5 ml of DCM are added to the reaction system. The reaction system is cooled to 0°C, and ethylsulfonyl chloride (7.8 mg, 0.06 mmol) is added dropwise. After the addition is completed, the reaction is allowed to proceed at room temperature for 1 hour. After the reaction is completed, water is added to quench the reaction, and DCM is added to extract the reaction mixture. The solution is separated, and the organic phase is washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. Concentrate and subject to column chromatography to obtain 22 mg of colorless oily product, the yield is 65.16%.

[0204] Synthesis of compound Ex-19: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)ethanesulfonamide The reaction mixture was added with intermediate 19-1 (22 mg, 0.03 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid, heated to 50° C. for 6 hours, concentrated, added with 4 ml of methanol and 0.5 ml of aqueous ammonia, concentrated, and purified by a silica gel plate to obtain 3 mg of a white solid, with a yield of 25.7%. LC-MS m / z (ESI) [M+H] + :C 21 H 23 The calculated value for FN5O3S is 444.1 and the measured value is 444.1.

[0205] Example 20: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-hydroxypiperidine-1-carboxamide (Ex-20) [ka]

[0206] Synthesis scheme of compound Ex-20: [ka]

[0207] Synthesis method: Intermediate 20-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-4-hydroxypiperidine-1-carboxamide (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (25.0 mg, 0.03 mmol) was dissolved in 5 ml of dry dichloromethane, cooled to 0° C., triphosgene (10.0 mg, 0.03 mmol) was added and reacted for 5 minutes, triethylamine (34.1 mg, 0.34 mmol) was slowly added and reacted for 30 minutes, and 4-hydroxypiperidine (4.1 mg, 0.04 mmol) was added and reacted at room temperature for 1 hour. The reaction mixture was added with water, extracted twice with dichloromethane, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 19.1 mg of intermediate 20-1, the yield being 65.2%.

[0208] Synthesis of compound Ex-20: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-hydroxypiperidine-1-carboxamide 20-1 (19.1 mg, 0.02 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified by preparative silica gel plate to obtain 3.6 mg of the final product, with a yield of 34.2%. 1 H NMR(400MHz,MeOD)δ8.29(d,J=8.0Hz,1H),7.43(d,J=4.0Hz,1H),7.19(dd,J=4.0Hz,J=8.0Hz,1H),7.09(s,1H),6.95(dd,J=12.0Hz,J=20.0 Hz,2H),4.44(s,2H),3.90-3.78(m,3H),3.13-3.06(m,2H),2.59-2.53(m,2H),1.90-1.85(m,2H),1.48-1.45(m,2H),1.08(t,J=8.0Hz,3H).

[0209] Example 21: (R)-N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxy-N-methylpyrrolidine-1-carboxamide (Ex-21) [ka]

[0210] Synthesis scheme of compound Ex-21: [ka]

[0211] Synthesis method: Synthesis of intermediate 21-1: 1-(2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)-N-methylmethylamine 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (50 mg, 0.07 mmol) and methylamine hydrochloride (5.3 mg, 0.08 mmol) were dissolved in DCM, and the solution was diluted with triethylamine. Add amine (9.8mg, 0.10mmol) and react at room temperature for 0.5 hours. Add sodium triacetoxyborohydride (28.6mg, 0.13mmol) to the reaction solution and react at room temperature for 1.5 hours. Add water to the reaction solution and extract with DCM twice. Combine the organic phases, wash with saturated saline, dry with anhydrous sodium sulfate, concentrate, and purify by silica gel plate to obtain 37mg of intermediate 21-1, the yield is 72.5%. 1 H NMR(400MHz,CDCl3)δ8.48(d,J=8.0Hz,1H),7.44(d,J=12.0Hz,2H),7.24(d,J=8.0Hz,1 H),7.15(d,J=8.0Hz,1H),6.99(d,J=12.0Hz,1H),5.91(s,2H),5.75(s,2H),5.32(s,2H) ),4.14(s,2H),3.86(t,J=10.0Hz,2H),3.56-3.62(m,4H),2.71(s,3H),2.51-2.57(m,2 H),1.05(t,J=8.0Hz,3H),0.86-0.91(m,6H),0.02-0.04(m,9H),-0.10--0.07(m,18H).

[0212] Synthesis of compound Ex-21: (R)-N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxy-N-methylpyrrolidine-1-carboxamide Dissolve triphosgene (14.5 mg, 0.05 mmol) in DCM, cool to 0° C., add dropwise a DCM solution of intermediate 21-1 (37 mg, 0.05 mmol) and react for 5 minutes, slowly add triethylamine (14.8 mg, 0.15 mmol) and react at 0° C. for 30 minutes, add dropwise a DCM solution of (R)-pyrrolidinebutan-3-ol (6.4 mg, 0.07 mmol) to the reaction solution and react at room temperature for 1 hour, The reaction mixture was added with water, extracted twice with DCM, the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified, the resulting product was dissolved in 2ml of methanol and 1ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 3ml of methanol, added with 0.5ml of aqueous ammonia, concentrated and purified by preparative silica gel plate to obtain 11mg of final product, the yield is 47.0%. 1 H NMR(400MHz,MeOD)δ8.28(d,J=8.0Hz,1H),7.43(s,1H),7.17-7.19(m,2H),6.90-6.97(m,2H),4.47(s,2H),4.40-4.42(m,1H),3. 62-3.75(m,2H),3.49-3.54(m,1H),3.37-3.38(m,1H),2.94(s,3H),2.53-2.58(m,2H),1.90-2.01(m,2H),1.08(t,J=8.0Hz,3H).

[0213] Example 22: (R)-N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide (Ex-22) [ka]

[0214] Synthesis scheme of compound Ex-22: [ka]

[0215] Synthesis method: Intermediate 22-1: Synthesis of (R)-N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (25.0 mg, 0.03 mmol) is dissolved in 5 ml of dry dichloromethane, cooled to 0° C., triphosgene (10.0 mg, 0.03 mmol) is added, and the mixture is reacted for 5 minutes. Triethylamine (34.1 mg, 0.34 mmol) is slowly added, and the mixture is reacted for 30 minutes. (R)-pyrrolidin-3-ol (3.5 mg, 0.04 mmol) is added, and the mixture is reacted at room temperature for 1 hour. The reaction mixture was added with water and extracted twice with dichloromethane, the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 21.0 mg of intermediate 22-1, the yield was 72.9%.

[0216] Synthesis of compound Ex-22: (R)-N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide 22-1 (21.0 mg, 0.02 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified by preparative silica gel plate to obtain 6.7 mg of the final product, with a yield of 58.6%. 1H NMR(400MHz,MeOD)δ8.29(d,J=8.0Hz,1H),7.43(d,J=4.0Hz,1H),7.19(d,J=8.0Hz,1H),7.11(s,1H),6.95(dd,J=12.0Hz,J=20. 0Hz,2H),4.45-4.43(m,3H),3.54-3.49(m,3H),3.40-3.37(m,1H),2.59-2.53(m,2H),2.08-2.02(m,2H),1.08(t,J=8.0Hz,3H).

[0217] Example 23: (S)-N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide (Ex-23) [ka]

[0218] Synthesis scheme of compound Ex-23: [ka]

[0219] Synthesis method: Intermediate 23-1: Synthesis of (S)-N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (25.0 mg, 0.03 mmol) is dissolved in 5 ml of dry dichloromethane, cooled to 0° C., triphosgene (10.0 mg, 0.03 mmol) is added, and the mixture is reacted for 5 minutes. Triethylamine (34.1 mg, 0.34 mmol) is slowly added, and the mixture is reacted for 30 minutes. (S)-pyrrolidin-3-ol (3.5 mg, 0.04 mmol) is added, and the mixture is reacted at room temperature for 1 hour. The reaction mixture was added with water, extracted twice with dichloromethane, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 17.8 mg of intermediate 22-1, the yield being 61.6%.

[0220] Synthesis of compound Ex-23: (S)-N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide 23-1 (17.8 mg, 0.02 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified by preparative silica gel plate to obtain 4.2 mg of the final product, with a yield of 43.5%. 1 H NMR(400MHz,MeOD)δ8.29(d,J=8.0Hz,1H),7.43(d,J=4.0Hz,1H),7.19(d,J=8.0Hz,1H),7.10(s,1H),6.95(dd,J=12.0Hz,J=20. 0Hz,2H),4.45-4.43(m,3H),3.53-3.49(m,3H),3.40-3.37(m,1H),2.59-2.53(m,2H),2.07-2.03(m,2H),1.08(t,J=8.0Hz,3H).

[0221] Example 24: 5-Ethyl-2-fluoro-4-(3-(4-(((2-hydroxyethyl)(methyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol (Ex-24) [ka]

[0222] Synthesis scheme of compound Ex-24: [ka]

[0223] Synthesis method: Synthesis of compound Ex-24: 5-ethyl-2-fluoro-4-(3-(4-(((2-hydroxyethyl)(methyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (20 mg, 0.03 mmol) and 2-(methylamino)ethan-1-ol (3 mg, 0.04 mmol) were dissolved in DCM and reacted at room temperature for 0.5 hours. Sodium triacetoxyborohydride (8.2 mmol) was added to the reaction solution. mg, 0.04mmol) was added and reacted at room temperature for 1.5 hours, water was added to the reaction solution, extracted with DCM twice, the organic phases were combined, washed with saturated saline, dried with anhydrous sodium sulfate, concentrated, and purified by silica gel plate, the purified concentrate was dissolved in 2ml of methanol, 1ml of concentrated hydrochloric acid was added, reacted at 50℃ for 6 hours, concentrated, dissolved in 3ml of methanol, 0.5ml of ammonia water was added, concentrated, and purified by silica gel plate to obtain 4.8mg of the final product, the yield is 43.4%. 1H NMR(400MHz,MeOD)δ8.34(d,J=8.0Hz,1H),7.51(s,1H),7.45(s,1H),7.22-7.17(m,1H),7.00-6.89(m,2H),4 .47(s,2H),3.98(t,J=4.0Hz,2H),3.43-3.37(m,2H),3.00(s,3H),2.60-2.51(m,2H),1.08(t,J=8.0Hz,3H).

[0224] Example 25: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propane-2-sulfonamide (Ex-25) [ka]

[0225] Synthesis scheme of compound Ex-25: [ka]

[0226] Synthesis method: Intermediate 25-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)propane-2-sulfonamide (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (17.0 mg, 0.02 mmol), TEA (7.0 mg, 0.07 mmol), and 5 ml of DCM are added to the reaction system. The reaction system is cooled to 0°C, and propane 2-sulfonyl chloride (7.4 mg, 0.05 mmol) is added dropwise. After the addition is completed, the reaction is allowed to proceed at room temperature for 1 hour. After the reaction is completed, water is added to quench the reaction, and DCM is added to extract the reaction mixture. The solution is separated, and the organic phase is washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate. Concentration and purification gave 11 mg of a colorless oily product, yield 56.6%.

[0227] Synthesis of compound Ex-25: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propane-2-sulfonamide The reaction mixture was added with intermediate 25-1 (11 mg, 0.01 mmol), 4 ml of MeOH, and 2 ml of concentrated hydrochloric acid, heated to 50° C. for 6 hours, concentrated, and then added with 4 ml of methanol and 0.5 ml of aqueous ammonia, concentrated, and purified by silica gel plate separation to obtain 3 mg of a white solid, with a yield of 50.5%. LC-MS m / z(ESI)[M+H] + :C 22 H 25 The calculated value for FN5O3S is 458.1 and the measured value is 458.1.

[0228] Example 26: ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methyl carbamate (Ex-26) [ka]

[0229] Synthesis scheme of compound Ex-26: [ka]

[0230] Synthesis method: Intermediate 26-1: Synthesis of ((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)methyl carbamate (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (30.0 mg, 0.04 mmol) was dissolved in 5 ml of dry dichloromethane, cooled to 0° C., triphosgene (11.9 mg, 0.04 mmol) was added, and the mixture was reacted for 5 minutes. Triethylamine (40.4 mg, 0.40 mmol) was slowly added, and the mixture was reacted for 30 minutes. The mixture was concentrated, and 2 ml of methanol was added to dissolve the mixture. DMAP (4.9 mg, 0.04 mmol) was added, and the mixture was heated to 70° C. and reacted for 4 hours. The reaction mixture was added with water, extracted twice with dichloromethane, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 17.9 mg of intermediate 26-1, the yield being 55.3%.

[0231] Synthesis of compound Ex-26: ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methyl carbamate 26-1 (17.9 mg, 0.02 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified by preparative silica gel plate to obtain 3.9 mg of the final product, with a yield of 42.5%. 1 H NMR(400MHz,MeOD)δ8.29(dd,J=4.0Hz,J=8.0Hz,1H),7.42(s,1H),7.17(dd,J=4.0Hz,J=8.0Hz,1H),7.10(s, 1H),6.95(dd,J=12.0Hz,J=20.0Hz,2H),4.39(s,2H),3.70(s,3H),2.58-2.53(m,2H),1.08(t,J=8.0Hz,3H).

[0232] Example 27: 2-Cyanoethyl ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)carbamate (Ex-27) [ka]

[0233] Synthesis scheme of compound Ex-27: [ka]

[0234] Synthesis method: Intermediate 27-1: Synthesis of 3-cyanoethyl ((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)carbamate Add 3-hydroxypropionitrile (10.1mg, 0.14mmol), 5ml of DMF, 0.2ml of triethylamine, and CDI (10.0mg, 0.06mmol) to the reaction system and react for 10 minutes, then add (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (30.0mg, 0.04mmol) and DMAP (0.6mg, 0.005ml). React at room temperature for 17 hours. After the reaction is completed, add water to quench, add EA to extract, wash the organic phase with ammonium chloride aqueous solution twice, wash with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 19 mg of colorless oily product by column chromatography, the yield is 57%.

[0235] Synthesis of compound Ex-27: 2-cyanoethyl ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)carbamate The reaction mixture was added with intermediate 27-1 (19 mg, 0.02 mmol), 4 ml of 1,4-dioxane, and 2 ml of concentrated hydrochloric acid, heated to 50° C. and reacted for 4 hours, concentrated, added with 4 ml of 1,4-dioxane and 0.5 ml of aqueous ammonia, concentrated, and purified by a silica gel plate for separation to obtain 2 mg of a white solid, with a yield of 20.0%. LC-MS m / z(ESI)[M+H] + :C 23 H 22 The calculated value for FN6O3 is 449.2 and the measured value is 449.2.

[0236] Example 28: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclobutaneformamide (Ex-28) [ka]

[0237] Synthesis scheme of compound Ex-28: [ka]

[0238] Synthesis method: Synthesis of compound Ex-28: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclobutaneformamide (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (30.0 mg, 0.04 mmol) was dissolved in 5 ml of dry dichloromethane, triethylamine (4.9 mg, 0.05 mmol) was added, and cyclobutylcarbonyl chloride (7.2 mg, 0.0 mmol) was added. 6mmol) was added and reacted at room temperature for 1 hour, water was added to quench, and extracted twice with dichloromethane. The organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product, which was dissolved in 4ml of methanol, then 2ml of concentrated hydrochloric acid was added, heated to 50°C and reacted for 6 hours, concentrated, dissolved in 2ml of methanol, 0.5ml of ammonia water was added, concentrated, and purified by preparative silica gel plate to obtain 7.0mg of the final product, with a yield of 39.9%. 1 H NMR(400MHz,MeOD)δ8.28(d,J=8.4Hz,1H),7.42(s,1H),7.17(dd,J=1.4Hz,J=8.4Hz,1H),7.10(s,1H),6.93(dd,J=11.8Hz,J=21.8Hz,2H ),4.45(s,2H),3.22-3.14(m,1H),2.55(q,J=7.6Hz,2H),2.37-2.27(m,2H),2.23-2.13(m,2H),2.07-1.96(m,2H),1.08(t,J=7.6Hz,3H).

[0239] Example 29: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methylpyrrolidine-3-carboxamide (Ex-29) [ka]

[0240] Synthesis scheme of compound Ex-29: [ka]

[0241] Synthesis method: Intermediate 29-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-1-methylpyrrolidine-3-carboxamide (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (50.0mg, 0.07mmol), 1-methylpyrrolidine-3-carboxylic acid (28.0mg, 0.16mmol), HATU (46.8mg, 0.12mmol), 10ml of DMF, 0.4ml of DIEA are added to the reaction system, and the mixture is stirred at room temperature for 2 hours. After the reaction is completed, the mixture is quenched by adding water, and EA is added to extract the mixture, and the solution is separated and dried with anhydrous sodium sulfate. The mixture is concentrated and subjected to column chromatography to obtain 28mg of a colorless oily product, with a yield of 40.0%.

[0242] Synthesis of compound Ex-29: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methylpyrrolidine-3-carboxamide The reaction mixture was added with intermediate 29-1 (28.0 mg, 0.03 mmol), 6 ml of MeOH, and 3 ml of concentrated hydrochloric acid, heated to 50° C. for 6 hours, concentrated, added with 4 ml of methanol and 0.5 ml of aqueous ammonia, concentrated, and purified by silica gel plate to obtain 2 mg of white solid, with a yield of 13.1%. LC-MS m / z(ESI)[M+H] + :C 25 H 28 The calculated value for FN6O2 is 463.2 and the measured value is 463.2.

[0243] Example 30: 4-(3-(4-((2-azabicyclo[2.2.2]octan-2-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol (Ex-30) [ka]

[0244] Synthesis scheme of compound Ex-30: [ka]

[0245] Synthesis method: Intermediate 30-1: Synthesis of 2-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-2-azabicyclo[2.2.2]octane The reaction system was charged with 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-3-yl)-1-(((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (55.0 mg, 0.08 mmol), 2-azabicyclo[2.2.2]octane (45.1 mg, 0.40 mmol), 10 ml of Add 1,2-dichloroethane and stir at room temperature for 2 hours, then add sodium triacetoxyborohydride (53.6 mg, 0.24 mmol) and react at room temperature. After the reaction is completed, add water to quench, add EA to extract, separate the solution, wash the organic phase with saturated sodium chloride solution, and dry with anhydrous sodium sulfate. Concentrate and obtain 36 mg of colorless oily product by column chromatography, the yield is 49.3%.

[0246] Synthesis of compound Ex-30: 4-(3-(4-((2-azabicyclo[2.2.2]octan-2-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol The reaction mixture was added with intermediate 30-1 (36 mg, 0.04 mmol), 6 ml of MeOH, and 3 ml of concentrated hydrochloric acid, heated to 50° C. and reacted for 6 hours. After concentrating, 4 ml of methanol was added, 0.5 ml of aqueous ammonia was added, concentrated, and purified by a silica gel plate to obtain 12 mg of a white solid, with a yield of 62.6%. LC-MS m / z(ESI)[M+H] + :C 26 H 29 The calculated value for FN5O is 446.2 and the measured value is 446.2.

[0247] Example 31: 4-(3-(4-((cyclobutylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol (Ex-31) [ka]

[0248] Synthesis scheme of compound Ex-31: [ka]

[0249] Synthesis method: Synthesis of compound Ex-31: 4-(3-(4-((cyclobutylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (20.0 mg, 0.03 mmol) and cyclobutanamine (3.1 mg, 0.04 mmol) were dissolved in DCM and reacted at room temperature for 0.5 hours. Triacetoxyborohydride sodium was added to the reaction solution. Add ethanol (8.2mg, 0.04mmol) and react at room temperature for 1.5 hours. Add water to the reaction solution, extract with DCM twice, combine the organic phases, wash with saturated saline, dry with anhydrous sodium sulfate, concentrate, purify, dissolve in 2ml of methanol, add 1ml of concentrated hydrochloric acid, react at 50℃ for 6 hours, concentrate, dissolve in 3ml of methanol, add 0.5ml of aqueous ammonia, concentrate, and purify by silica gel plate for separation to obtain 5.2mg of final product, the yield is 49.0%. 1 H NMR(400MHz,MeOD)δ8.39(d,J=8.0Hz,1H),7.45(s,1H),7.40(s,1H),7.22-7.17(m,1H),7.00-6.89(m,2H),4.19(s,2H) ),3.97-3.87(m,1H),2.62-2.51(m,2H),2.46-2.36(m,2H),2.3-2.22(m,2H),2.02-1.93(m,2H),1.08(t,J=8.0Hz,3H).

[0250] Example 32: 5-Ethyl-2-fluoro-4-(3-(4-(((tetrahydrofuran-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol (Ex-32) [ka]

[0251] Synthesis scheme of compound Ex-32: [ka]

[0252] Synthesis method: Intermediate 32-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)tetrahydrofuran-3-amine 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (20.0 mg, 0.03 mmol) was dissolved in 5 ml of dry dichloromethane, tetrahydrofuran-3-amine (3.5 mg, 0.04 mmol) was added, and the mixture was reacted at room temperature for 30 minutes, and sodium triacetoxyborohydride (8.6 mg, 0.04 mmol) was added, and the mixture was reacted at room temperature for 1 hour. The reaction mixture was added with water, extracted twice with dichloromethane, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 15.0 mg of intermediate 32-1, the yield being 68.4%.

[0253] Synthesis of compound Ex-32: 5-ethyl-2-fluoro-4-(3-(4-(((tetrahydrofuran-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol 32-1 (15.0 mg, 0.02 mmol) was dissolved in 2 ml of methanol, added with 1 ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, added with 0.5 ml of aqueous ammonia, concentrated, and purified by preparative silica gel plate to obtain 4.3 mg of the final product, with a yield of 55.1%. 1 H NMR(400MHz,MeOD)δ8.32(dd,J=4.0Hz,J=8.0Hz,1H),7.43(s,1H),7.20-7.17(m ,2H),6.95(dd,J=12.0Hz,J=20.0Hz,2H),4.01-3.96(m,1H),3.92(d,J=4.0Hz,2 H),3.90-3.87(m,1H),3.82-3.77(m,1H),3.72-3.69(m,1H),3.59-3.56(m,1H), 2.59-2.53(m,2H),2.24-2.17(m,1H),1.92-1.87(m,1H),1.08(t,J=8.0Hz,3H).

[0254] Example 33: 5-Ethyl-2-fluoro-4-(3-(4-((pyridin-2-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol (Ex-33) [ka]

[0255] Synthesis scheme of compound Ex-33: [ka]

[0256] Intermediate 33-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)pyridin-2-amine The intermediates 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-3-yl)-1-(((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-formaldehyde (30.0 mg, 0.04 mmol) and pyridin-2-amine (7.6 mg, 0.08 mmol) were added to 3 mL of 10 ... Dissolve in 1 ml of toluene, heat and stir at 100° C. for 20 hours, add sodium triacetoxyborohydride (17.0 mg, 0.08 mmol) to the reaction solution, and react at room temperature for 1 hour. Add water to the reaction solution to quench, extract twice with DCM, combine the organic phases, dry with anhydrous sodium sulfate, concentrate, and purify with a silica gel column to obtain 20.0 mg of intermediate 33-1, with a yield of 60.3%.

[0257] Synthesis of compound Ex-33: 5-ethyl-2-fluoro-4-(3-(4-((pyridin-2-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol 33-1 (18.0 mg, 0.02 mmol) was dissolved in 2 ml of methanol solution, and 1 ml of concentrated hydrochloric acid was added and reacted at 50° C. for 6 hours. The reaction solution was concentrated under vacuum, dissolved in 3 ml of methanol, and 0.5 ml of aqueous ammonia was added, concentrated, and separated on a silica gel plate to obtain 7 mg of the compound, with a yield of 74.3%. 1 H NMR(400MHz,MeOD)δ8.30(d,J=8.4Hz,1H),8.07-7.91(m,1H),7.50(ddd,J=8.7Hz,J=7.1Hz,J=1.9Hz,1H),7.42(s,1H) ),7.24-7.10(m,2H),7.01-6.85(m,2H),6.74-6.55(m,2H),4.57(s,2H),2.55(q,J=7.5Hz,2H),1.07(t,J=7.5Hz,3H).

[0258] Example 34: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methyl-1H-pyrazole-4-carboxamide (Ex-34) [ka]

[0259] Synthesis scheme of compound Ex-34: [ka]

[0260] Synthesis method: Synthesis of compound Ex-34: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methyl-1H-pyrazole-4-carboxamide 1-Methylpyrazole-4-carboxylic acid (7.4 mg, 0.06 mmol) is dissolved in 10 ml of DMF, HATU (22.4 mg, 0.06 mmol) and DIEA (12.7 mg, 0.06 mmol) are added, and the mixture is stirred at room temperature for 30 minutes. (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy))methyl)-1H-imidazol-4-yl)methanamine (30.0 mg, 0.04 mmol) is added, and the mixture is reacted at room temperature for 2 hours. Quench by adding water, extract twice with ethyl acetate, combine the organic phases, wash with saturated saline, dry with anhydrous sodium sulfate, concentrate to obtain a crude product, dissolve in 4ml of methanol, add 2ml of concentrated hydrochloric acid, heat to 50℃ and react for 6 hours, concentrate, dissolve in 2ml of methanol, add 0.5ml of aqueous ammonia, concentrate, and purify by preparative silica gel plate to obtain 8.0mg of final product, yield 43.1%. 1H NMR(400MHz,MeOD)δ8.29(d,J=8.3Hz,1H),8.10(s,1H),7.94(s,1H),7.42(s,1H),7.17(dd,J=1.4Hz,J=8.3Hz,1H),7. 16(s,1H),6.93(dd,J=11.7Hz,J=21.7Hz,2H),4.61(s,2H),3.94(s,3H),2.55(q,J=7.6Hz,2H),1.08(t,J=7.6Hz,3H).

[0261] Example 35: 5-Ethyl-2-fluoro-4-(3-(4-(((1-methylpyrrolidin-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol (Ex-35) [ka]

[0262] Synthesis scheme of compound Ex-35: [ka]

[0263] Synthesis method: Intermediate 35-1: Synthesis of N-((2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methyl)-1-methylpyrrolidin-3-amine 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (25.0 mg, 0.03 mmol) is dissolved in 5 ml of dry dichloromethane, 1-methylpyrrolidin-3-amine (5.1 mg, 0.05 mmol) is added, and the mixture is reacted at room temperature for 30 minutes, and sodium triacetoxyborohydride (10.7 mg, 0.05 mmol) is added, and the mixture is reacted at room temperature for 1 hour. The reaction mixture was added with water, extracted twice with dichloromethane, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 17.2 mg of intermediate 35-1, the yield being 61.8%.

[0264] Synthesis of compound Ex-35: 5-ethyl-2-fluoro-4-(3-(4-(((1-methylpyrrolidin-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol 35-1 (17.2 mg, 0.02 mmol) was dissolved in 2 ml of methanol, 1 ml of concentrated hydrochloric acid was added, and the mixture was reacted at 50°C for 6 hours, concentrated, dissolved in 2 ml of methanol, and 0.5 ml of aqueous ammonia was added. The mixture was concentrated and purified by a silica gel plate for separation to obtain 3.4 mg of the final product, with a yield of 37.6%. 1 H NMR(400MHz,MeOD)δ8.36(d,J=8.0Hz,1H),7.46(dd,J=4.0Hz,J=8.0Hz,2H),7.22-7.20(m,1H),6.95(dd,J=12.0Hz,J=20.0Hz,2H),4.22( s,2H),4.10-4.04(m,1H),3.67-3.54(m,3H),3.37-3.33(m,1H),2.96(s,3H),2.61-2.52(m,3H),2.32-2.21(m,1H),1.08(t,J=8.0Hz,3H).

[0265] Example 36: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)morpholine-4-carboxamide (Ex-36) [ka]

[0266] Synthesis scheme of compound Ex-36: [ka]

[0267] Synthesis method: Synthesis of compound Ex-36: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)morpholine-4-carboxamide Triphosgene (11 mg, 0.04 mmol) was dissolved in DCM, cooled to 0° C., and a DCM solution of (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (25.0 mg, 0.03 mmol) was added dropwise to the solution, reacted for 5 minutes, and triethylamine (10.2 mg, 0.10 mmol) was slowly added. The reaction mixture was stirred at 0°C for 0.5 hours, morpholine (4.4mg, 0.05mmol) was added to the reaction mixture, and the mixture was reacted at room temperature for 1 hour. Water was added to the reaction mixture, and the mixture was extracted twice with DCM. The organic phases were combined, washed with saturated saline, dried with anhydrous sodium sulfate, concentrated, and purified by silica gel plate. The resulting product was dissolved in 2ml of methanol and 1ml of concentrated hydrochloric acid, reacted at 50°C for 6 hours, concentrated, dissolved in 3ml of methanol, added with 0.5ml of aqueous ammonia, concentrated, and purified by separation plate to obtain 5mg of the final product, with a yield of 32.0%. 1H NMR(400MHz,MeOD)δ8.28(d,J=8.0Hz,1H),7.43(s,1H),7.18(d,J=8.0Hz,1H),7.10(s,1H),6.90-6.97(m ,2H),4.45(s,2H),3.68(t,J=4.0Hz,4H),3.43(t,J=4.0Hz,4H),2.53-2.58(m,2H),1.08(t,J=8.0Hz,3H).

[0268] Example 37: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-methylpiperazine-1-carboxamide (Ex-37) [ka]

[0269] Synthesis scheme of compound Ex-37: [ka]

[0270] Synthesis method: Synthesis of compound Ex-37: N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-methylpiperazine-1-carboxamide Dissolve triphosgene (11 mg, 0.04 mmol) in DCM, cool to 0°C, add dropwise a DCM solution of (2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-4-yl)methanamine (25 mg, 0.03 mmol) and react for 5 minutes, then slowly add triethylamine (10.2 mg, 0.10 mmol). Add 1-methylpiperazine (5.1mg, 0.05mmol) to the reaction solution and react at room temperature for 1 hour. Add water to the reaction solution, extract with DCM twice, combine the organic phase, wash with saturated saline, dry with anhydrous sodium sulfate, concentrate, purify, dissolve the obtained product in 2ml of methanol and 1ml of concentrated hydrochloric acid, react at 50°C for 6 hours, concentrate, dissolve in 3ml of methanol, add 0.5ml of ammonia water, concentrate, purify by separation plate to obtain 6mg of final product, yield is 37.3%. 1 H NMR(400MHz,MeOD)δ8.27(d,J=8.0Hz,1H),7.45(s,1H),7.19(d,J=8.0Hz,1H),7.16(s,1H),6.90-6.97(m,2H) ),4.46(s,2H),3.67-3.74(m,4H),3.10-3.15(m,4H),2.80(s,3H),2.53-2.58(m,2H),1.08(t,J=8.0Hz,3H).

[0271] Example 38: 5-Ethyl-4-(3-(4-((4-ethylpiperazin-1-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-2-fluorophenol (Ex-38) [ka]

[0272] Synthesis scheme of compound Ex-38: [ka]

[0273] Synthesis method: Intermediate 38-1: Synthesis of (6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-3-(4-((4-ethylpiperazin-1-yl)methyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole 2-(6-(2-ethyl-5-fluoro-4-((2-(trimethylsilyl)ethoxy)methoxy)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-3-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carbaldehyde (25.0 mg, 0.03 mmol) was dissolved in 5 ml of dry dichloromethane, 1-ethylpiperazine (5.8 mg, 0.05 mmol) was added, and the mixture was reacted at room temperature for 30 minutes, and sodium triacetoxyborohydride (10.7 mg, 0.05 mmol) was added, and the mixture was reacted at room temperature for 1 hour. The reaction mixture was added with water, extracted twice with dichloromethane, and the organic phases were combined, washed with saturated saline, dried over anhydrous sodium sulfate, concentrated and purified to obtain 23.0 mg of intermediate 32-1, the yield was 81.3%.

[0274] Synthesis of compound Ex-38: 5-ethyl-4-(3-(4-((4-ethylpiperazin-1-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-2-fluorophenol 38-1 (23.0 mg, 0.02 mmol) was dissolved in 2 ml of methanol, 1 ml of concentrated hydrochloric acid was added, and the mixture was reacted at 50° C. for 6 hours, concentrated, dissolved in 2 ml of methanol, 0.5 ml of aqueous ammonia was added, concentrated, and purified by a silica gel plate for separation to obtain 6.7 mg of the final product, with a yield of 54.5%. LC-MS m / z(ESI)[M+H] + :C 25 H 30 The calculated value for FN6O is 449.2 and the measured value is 449.2.

[0275] Experiment: Pharmacological activity evaluation 1. Experimental Principle A drug screening system based on JAK1, JAK2, JAK3, and TYK2 kinases is used to detect the inhibitory ability of each small molecule compound against kinase activity. The kinases and their substrates IRS1, IGF1Rtide, and Poly(4:1 Glu,Tyr) undergo an enzymatic reaction, consuming ATP to produce ADP, and the amount of the product is measured using a method that makes the ADP-Glo ​​reagent luminescent, which reflects the activity of the kinases.

[0276] 2. Experimental Method 2.1 Experimental materials and equipment [Table 1]

[0277] 2.2 Experimental Method 2.2.1 Kinase reaction reagent combination 2.2.1.1 1x Kinase Reaction Buffer (400 mL) [Table 2]

[0278] 2.2.1.2 2x Kinase Formulation [Table 3]

[0279] 2.2.1.3 Formulation of 4x Substrate Mixture [Table 4]

[0280] 2.2.2 Experimental steps of kinase reaction a) Dilute Filgotinib (10 mM stock solution) to original ratio using 100% DMSO, dilute test compounds 5-fold and 4-fold in the same ratio in a 96-well dilution plate, take 1 μL of compound and add it to 49 μL of kinase reaction buffer and shake on a microplate shaker for 20 minutes. b) 2 μL of kinase (prepared in step 2.2.1.2) is transferred to a 384 reaction plate and 1 μL of test compound (prepared in step a) is added to a 384 reaction plate (Greiner, 784075), centrifuged at 1000 rpm / min for 1 min and incubated at 25° C. for 10 min. c) 1 μL of the substrate mixture (prepared in step 2.2.1.3) is transferred to a 384 reaction plate, centrifuged at 1000 rpm / min for 1 minute, and incubated at 25° C. for 60 minutes. In the reaction system, the final concentrations of filgotinib are 50, 12.5, 3.125, 0.7812, 0.1953, 0.0488, 0.0122, 0.003, 0.00076, 0.00019, and 0.000047 μM. The final concentrations of the test compounds are 10, 2.5, 0.625, 0.15625, 0.039, 0.0097, 0.0024, 0.0006, 0.0015, 0.000038, and 0.0000095 μM. The final concentration of DMSO is 0.5% in all cases. d) Transfer 4 μL of ADP-Glo ​​to a 384 reaction plate, centrifuge at 1000 rpm / min for 1 minute, and incubate at 25° C. for 40 minutes. e) Transfer 8 μL of Detection solution to a 384 reaction plate, centrifuge at 1000 rpm / min for 1 minute, and incubate at 25° C. for 40 minutes. f) Use a Biotek multifunction plate reader to read the signal in RLU (Relative luminescence unit). The signal intensity is used to characterize the activity degree of the kinase.

[0281] 2.2.3 Experimental data processing method Compound inhibition rate (%inh) = (negative control - compound) / (negative control - positive control) x 100% Negative control: DMSO Positive control: filgotinib at 10μM / 50μM The IC50 (half maximal inhibitory concentration) of the compound is obtained using the following non-linear fitting equation: Y=Bottom+(Top-Bottom) / (1+10^((LogIC50-X)×HillSlope)) X: log value of compound concentration Y: Inhibition rate of the compound (%inh)

[0282] Z' coefficient calculation formula: Z'=1-3(SDmin+SDmax) / (AVEmax-AVEmin) During the ceremony, Min is the RLU value of the positive control filgotinib at 10 μM / 100 μM / 30 μM, and Max is the RLU value of the negative control DMSO. SD is the standard error and AVE is the mean RLU.

[0283] 3.Results 3.1 Quality control results of compound detection 3.1.1 Combining JAK1 and experimental quality control results Z'=0.79 CV%(min)=4% CV%(max)=5%

[0284] 3.1.2 Combining JAK2 and experimental quality control results Z'=0.74 CV%(min)=9% CV%(max)=8%

[0285] 3.1.3 Combining JAK3 and experimental quality control results Z'=0.76 CV%(min)=15% CV%(max)=6%

[0286] 3.1.4 Combination of TYK2 and experimental quality control results Z'=0.84 CV%(min)=8% CV%(max)=4%

[0287] 3.2 Summary of compound detection results [Table 5]

[0288] According to the above experimental results, the compounds detected in the present application can inhibit JAK1, JAK2, JAK3, and TYK2 at extremely low concentrations, and the inhibitory activity of the compounds in these examples far exceeds that of filgotinib.

[0289] Although specific embodiments of the present application have been illustrated and described, it is not intended that these embodiments illustrate and describe all possible forms of the present application. Rather, the characters described in the specification of the present application are descriptive and not limiting. It will be obvious to those skilled in the art that various other changes and modifications can be made without departing from the general scope of the present disclosure. It is therefore intended in the appended claims to cover all changes and modifications within the scope of the present application.

Claims

1. Formula (I): 【Chemistry 1】 or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer, or mixture of these isomers, or a pharma- ceutically acceptable salt thereof, wherein: L is C=O, O=S=O, CH 2 or a linked bond, X 1 is CH, X 2 is CH, X 3 is CH, R 13 is H, C 1-6 Alkyl or C 3-7 Cycloalkyl, 3- to 7-membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, 11-15 membered tricyclo, C 5-11 bicycloalkyl, 5- to 11-membered bicycloheteroalkyl, and R 13 is 0, 1, 2, 3 or 4 R 1 and R 17 is H, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4- to 10-membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl-, (5- to 10-membered heteroaryl)-C 1-4 Alkyl-, -C(=O)-N(R 9 ) (R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -S(=O) 2 -N(R 9 ) (R 10 wherein each option within the group is selected from the group consisting of halogen, —CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 13 and R 17 together with the L and N atoms to which they are attached form a 4-10 membered heterocycloalkyl, said 4-10 membered heterocycloalkyl being selected from the group consisting of halogen, -CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 18 and R 19 is H, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4- to 10-membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl-, (5- to 10-membered heteroaryl)-C 1-4 each independently selected from the group consisting of: halogen, —CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 18 and R 19 together with the carbon atoms attached thereto, 3-10 cycloalkyl, 4- to 10-membered heterocycloalkyl; 3-10 Cycloalkyl and 4-10 membered heterocycloalkyl are halogen, -CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 haloalkoxy; R 2 The number of R is 0, 1, 2, 3, or 4, and each R 2 is H, halogen, -OH, -NO 2 , -CN, -SF 5 , -SH, -S-C 1-4 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 4-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7- to 11-membered bicycloheteroaryl, -N(R 9 ) (R 10 ), -N(R 11 ) (C(=O)R 12 ), -C(=O)-N(R 9 ) (R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 ) (S(=O) 2 R 12 ), -S(=O) 2 -N(R 9 ) (R 10 ), -SR 12 and -OR 12 wherein -SC is independently selected from 1-4 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl and 7- to 11-membered bicycloheteroaryl are selected from halogen, —CN, —OH, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, -N(R 9 ) (R 10 ), -N(R 11 ) (C(=O)R 12 ), -C(=O)-OR 12 , -C(=O)H, -C(=O)R 12 , -C(=O)-N(R 9 ) (R 10 ), -N(R 11 ) (S(=O) 2 R 12 ), -S(=O) 2 -N(R 9 ) (R 10 ), -SR 12 and -OR 12 and optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of: Each R 1 is H, halogen, -OH, -NO 2 , -CN, -SF 5 , -SH, -S-C 1-4 Alkyl, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-8 Alkoxy, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl, 11-15 membered tricyclo, C 5-11 bicycloalkyl, 5- to 11-membered bicycloheteroalkyl, -N(R 9 ) (R 10 ), -N(R 11 ) (C(=O)R 12 ), -C(=O)-N(R 9 ) (R 10 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 ) (S(=O) 2 R 12 ), -S(=O) 2 -N(R 9 ) (R 10 ), -SR 12 and -OR 12 wherein -SC is independently selected from 1-4 Alkyl, C 1-8 Alkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-8 Alkoxy is one, two, three or four R 3 and 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7-11 membered bicycloheteroaryl is 1, 2, 3 or 4 R 4 optionally replaced by R 3 , R 4 is H, halogen, -OH, -NO 2 , -CN, -SF 5 , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl, 7- to 11-membered bicycloheteroaryl, -N(R 5 ) (R 6 ), -N(R 11 ) (C(=O)R 12 ), -CON(R 7 ) (R 8 ), -C(=O)-R 12 , -C(=O)-OR 12 , -OC(=O)R 12 , -N(R 11 ) (S(=O) 2 R 12 ), -S(=O) 2 -N(R 9 ) (R 10 ), -SR 12 and -OR 12 wherein each of said C 1-6 Alkyl, C 3-7 Cycloalkyl, 3-10 membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 Bicycloaryl and 7- to 11-membered bicycloheteroaryl are selected from halogen, —CN, —OH, C 1-4 Alkyl, C 1-6 Alkoxy, C 1-4 Haloalkyl, C 1-4 Haloalkoxy, C 3-6 Cycloalkyl, -N(R 9 ) (R 10 ), -N(R 11 ) (C(=O)R 12 ), -C(=O)-OR 12 , -C(=O)H, -C(=O)R 12 , -C(=O)-N(R 9 ) (R 10 ), -N(R 11 ) (S(=O) 2 R 12 ), -S(=O) 2 -N(R 9 ) (R 10 ), -SR 12 and -OR 12 and optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of: R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 are each independently H or C 1-6 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, (C 3-7 Cycloalkyl)-C 1-4 Alkyl-, (4- to 10-membered heterocycloalkyl)-C 1-4 Alkyl-, (C 6-10 Aryl)-C 1-4 Alkyl- and (5- to 10-membered heteroaryl)-C 1-4 alkyl-, where each option within the group is selected from the group consisting of halogen, —CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 optionally substituted with 1, 2, 3 or 4 substituents each independently selected from the group consisting of haloalkoxy; A compound, or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer, or mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

2. An isotopically labeled compound of formula (I), wherein all H are each independently optionally replaced with D.

2. A compound according to claim 1, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

3. L is C=O, O=S=O or CH 2 That is, 3. A compound according to claim 1 or 2, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

4. R 13 is H, C 1-6 Alkyl or C 3-7 Cycloalkyl, 3- to 7-membered heterocycloalkyl, C 5-7 Aryl, 5-7 membered heteroaryl, C 7-11 bicycloaryl, 7- to 11-membered bicycloheteroaryl, 11- to 15-membered tricyclo, and 1, 2, 3, or 4 R 1 optionally replaced by 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

5. R 13 is H, C 1-6 Alkyl or C 3-7 Cycloalkyl, 3- to 7-membered heterocycloalkyl, C 5-7 aryl, 5-7 membered heteroaryl, and 1, 2, 3 or 4 R 1 optionally replaced by 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

6. R 13 is C 1-6 Alkyl or C 3-7 cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, 5- to 6-membered heteroaryl, and 1, 2, 3, or 4 R 1 optionally replaced by 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

7. R 17 is H, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 aryl or 5-10 membered heteroaryl and halogen, -CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 optionally substituted with 1, 2, 3 or 4 substituents each independently selected from the group consisting of haloalkoxy; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

8. R 17 is H, C 1-6 Alkyl, C 3-7 cycloalkyl, 4- to 6-membered heterocycloalkyl, phenyl, or 5- to 6-membered heteroaryl, and halogen, —CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 optionally substituted with 1, 2, 3 or 4 substituents each independently selected from the group consisting of haloalkoxy; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

9. R 13 and R 17 together with the L and N atoms to which they are attached form a 4-6 membered heterocycloalkyl, said 4-6 membered heterocycloalkyl being selected from the group consisting of halogen, -CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 optionally substituted with 1, 2, 3 or 4 substituents each independently selected from the group consisting of haloalkoxy; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

10. R 18 and R 19 is H, C 1-6 Alkyl, C 1-4 Haloalkyl, C 2-8 Alkenyl, C 2-8 Alkynyl, C 1-6 Alkoxy, C 3-7 Cycloalkyl, 4-14 membered heterocycloalkyl, C 6-10 aryl and 5-10 membered heteroaryl, wherein each option within the group is selected from the group consisting of halogen, —CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 1-4 Hydroxyalkyl, -S-C 1-4 Alkyl, -C(=O)H, -C(=O)-C 1-4 Alkyl, -C(=O)-O-C 1-4 Alkyl, -C(=O)-NH 2 , -C(=O)-N(C 1-4 Alkyl) 2 , -N(C 1-4 alkyl)(C(=O)C 1-4 Alkyl), C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 optionally substituted with 1, 2, 3 or 4 substituents each independently selected from the group consisting of haloalkoxy; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

11. R 18 is H, 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

12. R 19 is H, 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

13. R 18 and R 19 are both H.

4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

14. R 18 and R 19 together with the carbon atoms attached thereto, 3-6 cycloalkyl, 4- to 6-membered heterocycloalkyl; 3-6 Cycloalkyl and 4- to 6-membered heterocycloalkyl are halogen, —CF 3 , —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -CN, oxo, C 1-4 optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of alkyl; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

15. 1, 2 or 3 R 2 and each R 2 is H, halogen, -OH, -NO 2 , -CN, -SF 5 , -SH, -S-C 1-4 Alkyl, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 cycloalkyl, and 4- to 10-membered heterocycloalkyl, wherein said -S-C 1-4 Alkyl, C 1-6 Alkyl, C 3-7 Cycloalkyl and 4- to 10-membered heterocycloalkyl are halogen, —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -C.N., C. 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of haloalkoxy; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

16. 1, 2 or 3 R 2 and each R 2 is halogen, C 1-6 Alkyl and C 3-6 cycloalkyl, wherein each of said C 1-6 Alkyl and C 3-6 Cycloalkyl is halogen, —OH, —NH 2 , -NH(CH 3 ), -N(CH 3 ) 2 , -C.N., C. 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy and C 1-4 optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of haloalkoxy; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

17. 1 or 2 R 2 and each R 2 is halogen, C 1-6 alkyl, 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

18. R 13 is 0 or 1 R 1 and R 1 is halogen, -OH, C 1-6 Alkyl, 5-7 membered heterocycloalkyl, C 3-7 cycloalkyl, wherein said C 1-6 Alkyl is one, two or three R 3 and the 5-7 membered heterocycloalkyl, C 3-7 Cycloalkyl is 1, 2, 3 or 4 C 1-3 optionally substituted with alkyl; 4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

19. The compound is N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-(piperidin-1-yl)pyrazine-2-carboxamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propionamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanecarboxamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)isobutyramide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methanesulfonamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-5-morpholinopyrazine-2-carboxamide, (S)-1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidin-3-ol, 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidin-4-ol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-N-methylcyclopropanecarboxamide, 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)piperidine-4-nitrile, 1-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)pyrrolidine-3-carbonitrile, 5-ethyl-2-fluoro-4-(3-(4-(morpholinomethyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 5-ethyl-2-fluoro-4-(3-(4-((pyridin-3-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 5-ethyl-2-fluoro-4-(3-(4-(((1-methyl-1H-pyrazol-4-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 3-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-(2-hydroxyethyl)-1-methylurea, 4-(3-(4-(((cyclopropylmethyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclopropanesulfonamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)ethanesulfonamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-hydroxypiperidine-1-carboxamide, (R)—N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxy-N-methylpyrrolidine-1-carboxamide, (R)—N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide, (S)—N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-3-hydroxypyrrolidine-1-carboxamide, 5-ethyl-2-fluoro-4-(3-(4-(((2-hydroxyethyl)(methyl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)propane-2-sulfonamide, ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)methyl carbamate, 2-cyanoethyl ((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)carbamate, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)cyclobutaneformamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methylpyrrolidine-3-carboxamide, 4-(3-(4-((2-azabicyclo[2.2.2]octan-2-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol, 4-(3-(4-((cyclobutylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-5-ethyl-2-fluorophenol, 5-ethyl-2-fluoro-4-(3-(4-(((tetrahydrofuran-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, 5-ethyl-2-fluoro-4-(3-(4-((pyridin-2-ylamino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-1-methyl-1H-pyrazole-4-carboxamide, 5-ethyl-2-fluoro-4-(3-(4-(((1-methylpyrrolidin-3-yl)amino)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)phenol, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)morpholine-4-carboxamide, N-((2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-1H-imidazol-4-yl)methyl)-4-methylpiperazine-1-carboxamide, 5-ethyl-4-(3-(4-((4-ethylpiperazin-1-yl)methyl)-1H-imidazol-2-yl)-1H-indazol-6-yl)-2-fluorophenol, Selected from:

4. A compound according to any one of claims 1 to 3, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof.

20. A compound according to any one of claims 1 to 19, or an isotopically labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer, or a mixture of these isomers, or a pharma- ceutically acceptable salt thereof; one or more pharma- ceutically acceptable carriers, adjuvants, or excipients; 13. A pharmaceutical composition comprising:

21. Use of a compound according to any one of claims 1 to 19, or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of these isomers, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 20, in the preparation of a medicament for treating and / or preventing a JAK-related disease or condition.

22. The JAK-associated disease or condition is selected from arthritis, autoimmune diseases or conditions, cancer or tumors, diabetes, eye diseases or conditions, intestinal inflammation or allergies, neurodegenerative diseases, skin diseases or conditions, allergies, asthma and other obstructive airway diseases, and transplant rejection.

22. The use according to claim 21.

23. A method for treating a JAK-associated disease or condition, comprising administering to a mammal other than a human a compound according to any one of claims 1 to 19, or an isotopically labeled compound thereof, or an optical isomer, geometric isomer, tautomer or mixture of these isomers, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 20.

24. The JAK-associated disease or condition is selected from arthritis, autoimmune diseases or conditions, cancer or tumors, diabetes, eye diseases or conditions, intestinal inflammation or allergies, neurodegenerative diseases, skin diseases or conditions, allergies, asthma and other obstructive airway diseases, and transplant rejection.

24. The method of claim 23.

Citation Information

Patent Citations

  • Indazole

    JP2014522865A

  • pyrazolopyridines and pyrazolopyrimidines

    JP2017515836A

  • JAK kinase inhibitor compounds for the treatment of respiratory diseases

    JP2018531982A

  • 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation

    US20050090529A1

  • 2,3-dihydro-isoindol-1-one derivative and a composition comprising the same

    WO2012047017A2